Document:

<PAGE>

                                                                     EXHIBIT 4.6

          THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN FILED SEPARATELY
          WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL
          TREATMENT REQUEST IN ACCORDANCE WITH RULE 24B-2 OF THE SECURITIES AND
          EXCHANGE ACT OF 1934, AS AMENDED. REDACTED PORTIONS OF THIS EXHIBIT
          ARE MARKED BY AN ***.

                     ASSET PURCHASE AND ASSIGNMENT AGREEMENT

          This Asset Purchase and Assignment Agreement (this "Agreement") is
     entered into as of November 3, 2005, (the "Effective Date") by and among
     Mylan Pharmaceuticals Inc., a West Virginia corporation ("Mylan Pharms"),
     and Mylan Bertek Pharmaceuticals Inc., a Texas corporation ("Bertek")
     (Mylan Pharms and Bertek, referred to herein individually and collectively
     as "Seller"), and Vernalis (R&D) Limited, a United Kingdom company
     ("Buyer"). Buyer and Seller are each sometimes referred to herein as a
     "Party" and collectively as the "Parties."

          WHEREAS, Buyer desires to acquire the Acquired Assets (as defined
     herein) and assume the Assumed Liabilities (as defined herein) from Seller;
     and

          WHEREAS, Seller desires to sell to Buyer such Acquired Assets and
     assign to Buyer such Assumed Liabilities, all as more particularly set
     forth in this Agreement.

          NOW, THEREFORE, for good and valuable consideration, the receipt and
     sufficiency of which are hereby acknowledged, the Parties, intending to be
     legally bound, hereby agree as follows:

                                    ARTICLE 1

                           DEFINITIONS; INTERPRETATION

          1.1 Definitions. Capitalized terms used in this Agreement, unless
     otherwise defined, shall have the meanings set forth below:

          "Acquired Assets" shall mean all of the following: (i) the Acquired
     Intellectual Property, (ii) Seller's rights under the Assigned Contracts,
     (iii) without prejudice to the Retained Japanese Rights, the Permits, (iv)
     the Books and Records, (v) the items described in Part 1 of Schedule
     2.4(b); and (vi) any other assets (if any) Controlled by Seller which
     relate solely to the Product. Notwithstanding any of the foregoing, the
     Acquired Assets shall not include the Excluded Assets or any other assets
     of the Seller. For the sake of clarity, Seller owns no equipment which is
     solely related to the Product.

          "Acquired Intellectual Property" shall mean (a) the Intellectual
     Property Rights set forth in Exhibit A; and (b) all Intellectual Property
     Rights owned or Controlled by Seller used solely for or in connection with
     the Product.

<PAGE>

          "Affiliate" shall mean, with respect to any Person, any other Person
     who directly or indirectly, through one or more intermediaries, controls,
     is controlled by, or is under common control with, such Person. For
     purposes of this definition only, the term "control" shall mean the
     possession, directly or indirectly, of the power to direct or cause the
     direction of the management and policies of a Person, whether through the
     ownership of voting securities, by contract or otherwise, and the terms
     "controlled" and "controlling" have meanings correlative thereto.

          "Assigned Contracts" shall mean the Contracts set forth on Exhibit B
     hereto.

          "Assumed Liabilities" shall mean, subject to the terms and conditions
     of this Agreement, the following liabilities and obligations of Seller to
     the extent related to the period on and following Closing: (i) all
     liabilities, obligations, responsibilities and commitments of Seller under
     the Assigned Contracts, except those liabilities related to the Cost of
     Goods as described n Section 2.2 of the Transition Period Services
     Agreement which liability for Cost of Goods will be assumed by Buyer
     following the transition of the supply chain activity Services to Buyer as
     described in Section 1.5 of the Transition Period Services Agreement and
     (ii) all regulatory liabilities, obligations, responsibilities and
     commitments of Seller pursuant to or arising from the Permits including,
     without limitation, the Post-Marketing Commitments.

          "Books and Records" shall mean the books, records, documentation,
     data, databases (excluding Third Party software), and other information
     described in Exhibit F hereto.

          "Business Day" shall mean any day on which banking institutions are
     not required or authorized to close in New York, New York.

          "Buyer's Knowledge" means Buyer's and its Affiliates' knowledge having
     made reasonable investigation with respect to any such facts and
     information.

          "Contract" shall mean any contract, agreement, indenture, note, bond,
     loan, instrument, lease, conditional sale contract, mortgage, license,
     franchise, insurance policy, commitment or other arrangement or agreement,
     whether written or oral.

          "Control" shall mean possession of the right, whether directly or
     indirectly, and whether by ownership, license or otherwise (without the
     need to obtain consent), to assign, or grant a license, sublicense or other
     right as provided for herein without violating the terms of any agreement
     or other arrangement with any Third Party.

          "Encumbrances" shall mean any claim, lien, pledge, option, charge,
     deed of trust, security interest, mortgage, encumbrance, restriction on
     transfer (such as a right of first refusal or other similar rights, but not
     including any restrictions on transfer arising under federal or state
     securities laws), defect of title or other similar right of any Third Party
     whether voluntarily incurred or arising by operation of law, and includes
     any agreement to give any of the foregoing in the future, and any
     contingent sale or other title retention agreement or lease in the nature
     thereof.

          "Excluded Assets" shall mean the

          (a) Retained Japanese Rights;

                                        2

<PAGE>

          (b) all Contracts other than the Assigned Contracts provided that upon
     assignment of the Vetter Agreement to the Buyer, the Vetter Agreement shall
     be an Assigned Contract; and

          (c) all inventory of Product other than that listed in Part 1 of
     Schedule 2.4(b)

          "Excluded Liabilities" shall mean all debts, obligations, taxes,
     duties and liabilities of Seller and its Affiliates (all of which are
     expressly excluded from the purchase and sale contemplated hereby), other
     than the Assumed Liabilities. For the sake of clarity, Excluded Liabilities
     shall include (i) any liability or obligation of Seller under this
     Agreement and the other Transaction Documents, (ii) any payment or credit
     obligation under an Assigned Contract which arises after Closing but which
     relates to sales occurring, or services or activities conducted prior to,
     Closing, and (iii) all other liabilities of Seller other than as expressly
     contemplated by the definition of "Assumed Liabilities."

          "FDA" shall mean the U.S. Food and Drug Administration, or any
     successor entity thereto.

          "FDCA" shall mean the Federal Food, Drug and Cosmetic Act of 1938, as
     amended.

          "Governmental Entity" shall mean any federal, state, local or foreign
     governmental, regulatory or administrative body, agency, department, board,
     commission or governmental entity or unit, any court or judicial
     governmental entity, any public, private or industry regulatory
     governmental entity, whether federal, state, local, foreign or otherwise,
     or any Person lawfully empowered by any of the foregoing to enforce or seek
     compliance with any Law.

          "IND" shall mean the Investigational New Drug Application 52,844.

          "Intellectual Property Rights" means the rights associated with or
     arising out of any of the following: (a) trade secret rights and
     corresponding rights in confidential information and other non-public
     information (whether or not patented or patentable), including ideas,
     formulas, compositions, inventor's notes, discoveries and improvements,
     know-how, manufacturing and production processes and techniques, testing
     information, research and development information, inventions, invention
     disclosures, unpatented blueprints, drawings, specifications, designs,
     plans, proposals and technical data, business and marketing plans, market
     surveys, market know-how and customer lists and information; (b) all
     trademarks, service marks, logos, domain names, copyrights, database
     rights, design rights, trade dress and trade names, and other indicia of
     commercial source or origin (whether registered, common law, statutory or
     otherwise), all registrations and applications to register the foregoing
     anywhere in the world and all goodwill associated therewith; and (c) any
     similar, corresponding or equivalent rights to any of the foregoing
     anywhere in the world.

          "Interim Agreement" shall mean the agreement set out in Exhibit G.

          "Law" or "Laws" shall mean any applicable federal, state, local or
     foreign law, statute, constitution, ordinance, decree, requirement, code,
     order, judgment, injunction, restriction, rule or regulation in effect of
     any Governmental Entity.

          "Loss" or "Losses" shall mean any and all losses, liabilities, costs,
     deficiencies, fines, damages, penalties and expenses, and any legal or
     other reasonable expenses incurred in

                                        3

<PAGE>

     connection with investigating or defending any claim, whether or not
     resulting in damages; provided, however, that indirect, incidental,
     consequential and punitive damages shall not be included in any calculation
     of "Losses" except to the extent awarded in a Third Party claim.

          "NDA" shall mean the New Drug Application 21-264.

          "North America" shall mean the United States of America, its
     territories and possessions (including the freely-associated Commonwealth
     of Puerto Rico), Canada and Mexico.

          "Open Final Study Reports" shall have the meaning given to it in the
     Transition Period Services Agreement.

          "Orphan Drug Designation" shall mean the FDA's act of granting a
     request for designation of the Product as intended for a rare disease or
     condition pursuant to the Orphan Drug Act 1983 Section 526 or 21 CFR
     316.24.

          "Permits" shall mean the NDA, IND, and the Orphan Drug Designation.

          "Person" shall mean an individual, partnership, corporation, limited
     liability company, joint stock company, unincorporated organization or
     association, trust, joint venture, association or other organization,
     whether or not a legal entity, or any Governmental Entity.

          "Post-Marketing Commitments" shall mean any and all obligations,
     responsibilities and commitments required by the FDA and/or other
     Governmental Entity with respect to the Product and/or the Permits, whether
     outstanding as of Closing or arising thereafter, except the Open Final
     Study Reports which Seller shall be responsible for completing to the
     extent and only to the extent set forth in the Transition Period Services
     Agreement. Buyer acknowledges that attached hereto as Exhibit E is the
     status of the outstanding Post-Marketing Commitments as of the Effective
     Date.

          "Product" shall mean the pharmaceutical product APOKYN(TM)
     (apomorphine hydrochloride subcutaneous injection), as described on Exhibit
     C hereto.

          "Registered IP" means any Acquired Intellectual Property that is the
     subject of an application, certificate, filing, registration or other
     document issued, filed with, or recorded by any Governmental Entity,
     including any trademark registrations and applications.

          "Retained Japanese Rights" means the retained rights of Seller (a) to
     possess a copy of the NDA but excluding the right to use or exploit the
     same save as provided in (b) and (b) to convey to Britannia
     Pharmaceuticals, Limited or its nominee the transferable and sublicensable
     right to possess a copy of the NDA and to use the information and
     Intellectual Property Rights therein solely in Japan and solely for the
     purposes related to or relevant to the importation, use, development,
     manufacture, marketing and sale of apomorphine products (regardless of form
     or formulation) in Japan.

          "Seller's Knowledge" means Seller's and its Affiliates' knowledge
     having made reasonable investigation with respect to any such facts and
     information.

                                        4

<PAGE>

          "Taxes" shall mean all taxes, charges, fees, duties, levies, or other
     assessments of any kind whatsoever, including (without limitation) income,
     gross receipts, net proceeds, ad valorem, turnover, real and personal
     property (tangible and intangible), sales, use, franchise, excise, value
     added, stamp, user, transfer, fuel, excess profits, occupational, interest
     equalization, windfall profits, and employees' income withholding,
     unemployment and Social Security taxes, which are imposed by the United
     States, or any state, local or foreign government or subdivision or agency
     thereof, including any interest, penalties or additions to tax related
     thereto.

          "Tax Return" shall mean any return, declaration, report, claim for
     refund or information return or statement relating to Taxes, including any
     schedule or attachment thereto and including any amendment thereof.

          "Third Party" shall mean any Person other than Buyer, Seller and their
     respective Affiliates.

          "Transaction Documents" shall mean this Agreement, the Transition
     Period Services Agreement, the Bill of Sale, the IP Assignments, and the
     other documents, instruments, exhibits, annexes, schedules, or certificates
     contemplated hereby and thereby.

          "Transition Period Services Agreement" shall mean that agreement
     between the Parties pertaining to the delivery of specified support
     services by Seller to Buyer for a limited period following Closing in the
     form specified in Exhibit D.

          "Vetter Agreement" shall mean the Supply Agreement by and between
     Mylan Pharmaceuticals Inc. and Vetter Pharma-Fertigung GmbH & Co. KG
     ("Vetter") dated as of April 1, 2004, as well as the corresponding Quality
     Agreement.

          1.2 Other Defined Terms. The following terms are defined in the
     sections indicated.

<TABLE>
<S>                                    <C>
Bill of Sale........................   Section 3.2(c)
Closing.............................   Section 3.1
Confidentiality Agreement...........   Section 6.4
Costs...............................   Section 3.5
Disputes............................   Section 4.8(c)
Indemnified Party...................   Section 7.4(a)
IP Assignments......................   Section 3.3(c)
Purchase Price......................   Section 2.4
Required Consents...................   Section 3.3(f)
Services............................   Transition Period
                                       Services Agreement
Transfer Taxes......................   Section 6.5
Transition Team.....................   Transition Period
                                       Services Agreement
</TABLE>

          1.3 Business Days. Whenever the last day for the exercise of any
     privilege or the discharge of any duty hereunder shall fall upon any day
     which is not a Business Day, the party having such

                                        5

<PAGE>

     privilege or duty may exercise such privilege or discharge such duty on the
     next succeeding Business Day.

          1.4 Terminology. Unless otherwise indicated to the contrary herein by
     the context or use thereof: (i) the words, "herein," "hereto," "hereof" and
     words of similar import refer to this Agreement as a whole and not to any
     particular Section or paragraph hereof; (ii) the word "including" shall
     mean "including, but not limited to"; (iii) masculine gender shall also
     include the feminine and neutral genders, and vice versa; (iv) words
     importing the singular shall also include the plural, and vice versa; and
     (v) references to statutes shall include all regulations promulgated
     thereunder and references to statutes or regulations shall be construed as
     including any and all further statutory and regulatory provisions
     consolidating, amending, expanding, implementing, or replacing the statute
     or regulation.

                                    ARTICLE 2

                          PURCHASE AND SALE OF ASSETS;
                            ASSIGNMENT AND ASSUMPTION

          2.1 Purchase and Sale of Assets. On and subject to the terms and
     conditions of this Agreement, Buyer agrees to purchase from Seller at
     Closing, and Seller agrees to sell, transfer, convey, assign and deliver to
     Buyer at Closing, all of the Acquired Assets at Closing for the
     consideration specified below in Section 2.4.

          2.2 Assignment of Contracts and Permits.

     (a) Subject to the terms and conditions of this Agreement, Seller will
assign and transfer to Buyer, and Buyer will accept and assume from Seller,
effective as of Closing, Seller's right, title and interest in and to, the
Assigned Contracts and all of the Permits save for the Retained Japanese Rights.

               Anything in this Agreement to the contrary notwithstanding, this
     Agreement shall not constitute an agreement to assign or transfer any
     Contract or Permit or any claim or right or any benefit or obligation
     thereunder or resulting therefrom if an assignment or transfer thereof,
     without the consent of a Third Party thereto, would constitute a breach or
     violation thereof or is otherwise prohibited. If such consent is required
     or if an attempted assignment is ineffective, Seller shall use its
     commercially reasonable efforts to secure such consent as soon as possible
     after Closing and, pending receipt of such consent shall cooperate with
     Buyer to provide for Buyer the benefits under any such Assigned Contract or
     Permit.

     (b) In relation to those Contracts (other than the Assigned Contracts and
the Vetter Agreement) copies of which are received by Buyer from Seller prior to
Closing, Seller is free to terminate any such Contract. In Seller's sole
discretion, Seller may, within sixty (60) days after Closing, present to Buyer
any Contract regarding the Product or Acquired Assets for Buyer's consideration
to assume. If Buyer provides written notice to Seller within ten (10) Business
Days of such presentation by Seller that Buyer desires to assume said Contract,
Seller will cooperate to effect such assignment of the Contract to Buyer. Any
Contract so assumed shall be deemed to be an Assigned Contract as of Closing for
the purposes of this Agreement and Exhibit B shall be deemed to be amended
accordingly.

                                        6

<PAGE>

          2.3 Assumption of Liabilities. On and subject to the terms and
     conditions of this Agreement, Buyer agrees to assume and become responsible
     for all of the Assumed Liabilities from and after Closing. Buyer will not
     assume or have any responsibility, however, with respect to any Excluded
     Liabilities.

          2.4 Purchase Price. In consideration for the sale of the Acquired
     Assets by Seller to Buyer, Buyer shall pay to Seller

          (a) an amount of Twenty-Three Million US Dollars (US $23,000,000.00)
     at Closing (the "Purchase Price"); and

          (b) an amount equal to a dollar-for-dollar true-up for the sum of (a)
     those items listed in Part 1of Schedule 2.4(b); and (b) any additional
     inventory of Product ordered by Seller on Buyer's instructions after the
     Closing and paid for by Seller pursuant to Section 2.2. of the Transition
     Period Services Agreement, less the amounts paid by Buyer for any such
     items and inventory pursuant to Section 2.2 of the Transition Period
     Services Agreement. Such amount shall be calculated and paid within thirty
     (30) days of expiry of receipt of the other items listed in Schedule 2.4(b)
     and of the inventory of Product remaining following expiry of the Service
     Period of the Supply Chain Activity Services as provided in Section 1.5(b)
     of the Transition Period Services Agreement.

          2.5 Payment of Purchase Price. Payment by Buyer of the Purchase Price
     shall be made by the transfer of immediately available funds to an account
     in the US designated by Seller.

                                   ARTICLE 3

                               CLOSING; DELIVERIES

          3.1 The Closing. The closing of the sale and purchase of the Acquired
     Assets (the "Closing") shall take place at the offices of the Seller at 781
     Chestnut Ridge Road, Morgantown, West Virginia, at 10:00 a.m., local time,
     on the Effective Date. At the Closing, the Parties will exchange funds,
     certificates and other documents as specified in this Agreement.

          3.2 Deliveries by Buyer. At the Closing, Buyer shall deliver to Seller
     the following:

     (a) cash in the non-refundable amount of Twenty Three Million Dollars
($23,000,000.00). For clarity the amounts to be computed pursuant to Section
2.4(b) shall be paid in accordance with Section 3.5;

     (b) a counterpart to the Transition Period Services Agreement in the form
of Exhibit D hereto and a counterpart to the Interim Agreement in the form of
Exhibit G hereto, each duly executed on behalf of Buyer;

     (c) a counterpart to a Bill of Sale and Assignment and Assumption Agreement
in substance consistent with this Agreement and in customary form (the "Bill of
Sale"), duly executed on behalf of Buyer;

                                        7

<PAGE>

     (d) a certified copy of a resolution of Buyer's Board of Directors
approving the transactions contemplated by this Agreement; and

     (e) the letters set out in Schedule 3.2(e) duly executed on behalf of
Buyer.

     (f) a copy of a search against the Buyer conducted at Companies House dated
a recent date prior to the Closing.

          3.3 Deliveries by Seller. At the Closing, Seller shall deliver to
     Buyer the following:

     (a) a counterpart to the Transition Period Services Agreement, and a
counterpart to the Interim Agreement in the form of Exhibit G hereto, each duly
executed on behalf of Seller;

     (b) a counterpart to the Bill of Sale, duly executed on behalf of Seller;

     (c) assignments (the "IP Assignments") of the Acquired Intellectual
Property identified in Part 1 of Exhibit A, in customary form;

     (d) a certificate from the Secretaries of State of West Virginia and of
Texas, dated a recent date prior to the Closing, certifying as to Seller's good
standing;

     (e) a certificate from the Secretary of Seller, certifying as to Seller's
certificate of incorporation and by-laws, and actions taken by the Board of
Directors of Seller approving the transactions contemplated by this Agreement;

     (f) the consents ("Required Consents") set forth on Schedule 3.3(f); and

     (g) the letters set out in Schedule 3.3(g) duly executed on behalf of
Seller.

          3.4 Post Closing Accounts Arrangements. For all credits price
     concessions, rebates, administrative fees, reimbursements, chargebacks,
     rejections, returns (including the cost of destroying any return) and
     similar ("Costs") (as referred to in the Transition Period Services
     Agreement, Section 2.2) paid or issued subsequent to Closing that pertain:

          (a)  to the sale of Product prior to Closing, Seller shall be
               responsible for those Costs; and

          (b)  to the sale of the Product subsequent to Closing, Buyer shall be
               responsible for those Costs.

          Buyer shall reimburse the Seller, and Seller shall reimburse Buyer,
          for any payments made by it for which the other is responsible
          pursuant to this Section, in each case against invoice. Determination
          of liability for any particular Cost shall be made using the
          methodology that most accurately and reasonably allocates Costs as
          outlined above, such as lot number of the Product sold, or where it is
          not possible to determine the lot number of Product sold, by the
          timing between incurring the Cost and the time of actual payment (such
          time lag to be reasonable to both Parties) or such other method as the
          Parties may agree. If the Parties cannot agree on allocation of any
          Cost, the calculation will be submitted for determination

                                        8

<PAGE>

          to an international, independent public accounting firm mutually
          selected by the Parties, and such determination will be binding on the
          Parties. For ease of administration, the Parties agree to accept the
          following assumptions:

          (i)  for Medicaid rebates, rebates that are claimed within 180 days of
               Closing will be deemed to pertain to Seller's sales and rebates
               claimed thereafter (or any with Buyer's label) will be deemed to
               pertain to Buyer's sales;

          (ii) with respect to returns, each Party is responsible for all
               returns relating to entire lots of Product sold by it. Where each
               Party has sold part of a lot of Product, unless otherwise agreed,
               returns will be destroyed and the responsibility for the Costs of
               such returns will be allocated between Buyer and Seller in
               proportion to volume of sales of Product made by it from that
               lot. The Parties believe the above calculation would be the most
               reasonable basis for allocating returns, however, if after
               reviewing the actual return activity, a Party believes an
               alternate basis is more accurate it may propose such alternate
               basis. If the Parties cannot agree on the suggested alternate
               allocation of returns, the calculation will be submitted for
               determination to an international, independent public accounting
               firm mutually selected by the Parties, and such determination
               will be binding on the Parties.

          3.5. Transfer / Delivery of Acquired Assets. The Parties agree that
     the transfer/delivery off the Acquired Assets from Seller to Buyer shall be
     done in accordance with the terms set forth in the Transition Period
     Services Agreement. The Parties acknowledge that Seller may retain a copy
     of all Books and Records for regulatory, liability or archival purposes as
     set out in the Transition Period Services Agreement.

                                   ARTICLE 4

                    REPRESENTATIONS AND WARRANTIES OF SELLER

          Seller represents and warrants to Buyer as of the Effective Date:

          4.1 Corporate Organization; Authority. Mylan Pharms is a corporation
     duly organized, validly existing and in good standing under the laws of the
     State of West Virgina, and has all requisite corporate power and authority
     to conduct its business as it is now being conducted and to own, lease and
     operate its properties and assets. Bertek is a corporation duly organized,
     validly existing and in good standing under the laws of the State of Texas,
     and has all requisite corporate power and authority to conduct its business
     as it is now being conducted and to own, lease and operate its properties
     and assets.

          4.2 Authority Relative to this Agreement. Seller has all requisite
     power and authority (including corporate power or authority) to execute and
     deliver this Agreement and the other Transaction Documents to which it is a
     party and to consummate the transactions provided for herein and therein.
     The execution and delivery by Seller of this Agreement and the other
     Transaction Documents to which it is a party and the consummation of the
     transactions contemplated hereby and thereby have been duly and validly
     authorized by the Board of Directors, and no other corporate proceedings on
     the part of Seller are necessary to authorize this Agreement

                                        9

<PAGE>

     or the other Transaction Documents to which it is a party or to consummate
     the transactions contemplated hereby or thereby. This Agreement has been
     duly and validly executed and delivered by Seller, and, assuming this
     Agreement has been duly authorized, executed and delivered by Buyer, this
     Agreement constitutes a valid and binding agreement of Seller, enforceable
     against Seller in accordance with its terms, except that such enforcement
     may be subject to bankruptcy, insolvency, reorganization, moratorium
     (whether general or specific) or other similar Laws now or hereafter in
     effect relating to creditors' rights generally.

          4.3 No Violations; Consents and Approvals. Except as set forth in
     Schedule 4.3, neither the execution and delivery by Seller of this
     Agreement or the other Transaction Documents to which it is a party, nor
     the consummation of the transactions contemplated hereby or thereby, will
     (a) violate any Law, ruling or other restriction of any Governmental Entity
     to which Seller is subject, (b) breach or violate any provision of the
     Certificate of Incorporation or By-laws of Seller, (c) conflict with,
     result in a material breach of, result in the acceleration of, result in a
     notice obligation under, create in any party a right to accelerate,
     terminate or modify or cancel, any Contract to which Seller is a party or
     by which Seller is bound, (d) result in the creation of any Encumbrance
     upon the Acquired Assets, or (e) except as otherwise expressly contemplated
     by this Agreement, require any consent, waiver, approval, authorization of,
     permit from, filing with, or notification to any Governmental Entity or any
     other Person in connection with the execution, delivery and performance of
     this Agreement and the other Transaction Documents and the consummation of
     the transactions contemplated hereby and thereby; provided, however, that
     this Section 4.3 shall not extend to any consent, waiver, approval,
     authorization, Permit, filing or notification that may be required due to
     Buyer's status as a foreign entity. This Section does not affect Section
     2.2(b).

          4.4 Compliance with Law. Seller has complied in all material respects
     with all Laws applicable to the Product, the Acquired Assets and the
     Assumed Liabilities (and any of them) and Seller's operations in connection
     therewith and no action, suit, proceeding, hearing, investigation, charge,
     complaint, claim, demand or notice has been filed or commenced against
     Seller alleging any failure to so comply.

          4.5 Assigned Contracts. With respect to each Assigned Contract and the
     Vetter Agreement, except as set forth in Schedule 4.5(a): (i) such Assigned
     Contract and the Vetter Agreement is in full force and effect; (ii) Seller
     is not in material breach or default thereunder, and, to Seller's
     Knowledge, no event has occurred which with notice or lapse of time would
     reasonably be expected to constitute a material breach or default, or
     permit termination, modification, or acceleration, under such Assigned
     Contract or the Vetter Agreement; (iii) neither Seller nor, to Seller's
     Knowledge, any other party to such Assigned Contract or the Vetter
     Agreement has repudiated any material provision thereof; and (iv) Seller
     has not received any notice that it has violated, defaulted under or
     breached such Assigned Contract or the Vetter Agreement. Other than the
     Assigned Contracts and the Contracts copies of which were received by Buyer
     from Seller prior to the Effective Date (including the Vetter Agreement),
     Seller has not entered into any Contract which is at the Effective Date
     material to the Product.

          4.6 Litigation. Except as set forth on Schedule 4.6, there is not
     currently and has not been previously any action, suit or proceeding
     pending, decided or settled or, to Seller's Knowledge, threatened, against
     Seller, relating in any way to the Product, the Acquired Assets or the
     Assumed

                                       10

<PAGE>

     Liabilities (or any of them) or to Seller's operations in connection
     therewith, before any court or Governmental Entity or arbitral body or
     other dispute resolution body. There is no investigation or inquiry being
     conducted or, to Seller's Knowledge, threatened, by any Governmental Entity
     involving Seller, or relating to Seller's use, development,
     commercialization or manufacture of the Product. Except as set forth in
     Schedule 4.6, Seller has not received notice that it is subject to any
     outstanding judgment, order, injunction, default notice or decree of any
     Governmental Entity.

          4.7 Rights in Acquired Assets. Save for those Acquired Assets
     identified in Schedule A as being licensed to Seller, Seller has good title
     to all of the Acquired Assets, free and clear of all Encumbrances. With
     respect to those Acquired Assets identified in Schedule A as being licensed
     to Seller, Seller's license interest is valid and subsisting and free of
     all Encumbrances. Following consummation of the transactions contemplated
     by this Agreement, Buyer will have the same rights, titles, and interests
     in and to the Product and the Acquired Assets from and after Closing as
     Seller has on the date immediately prior to the Effective Date. The
     Acquired Assets, together with the (a) the Contracts copies of which were
     received by Buyer from Seller prior to the Effective Date; and (b) the
     inventory listed in Part 2 of Schedule 2.4(b); constitute all assets and
     rights owned or Controlled by Seller and any of its Affiliates which are
     material to the Product.

          4.8 Intellectual Property.

     (a) Except as expressly stated in Schedule 4.8, all of the Acquired
Intellectual Property is either (i) wholly and exclusively owned by Seller free
and clear of all options, rights, licenses, restrictions, interests of any kind,
and Encumbrances or (ii) duly, validly, wholly, and exclusively licensed to
Seller in North America and Seller's license interest is valid and subsisting
and free of all Encumbrances. Schedule A accurately identifies which Acquired
Intellectual Property is owned by Seller and which is licensed to Seller.

     (b) There are no claims pending or, to Seller's Knowledge, threatened, with
regard to the use, ownership or licensing to or by Seller of any of the Acquired
Intellectual Property. As of the Effective Date, Seller has and as of Closing
Seller will have the legal power to convey to Buyer all of its ownership and
license interests in the Acquired Intellectual Property.

     (c) There is not currently and there has not been previously, any pending,
decided or settled injunction, claim, lawsuit, proceeding, hearing,
investigation, complaint, arbitration, mediation, demand, ITC investigation,
decree, or any other dispute, disagreement, or claim related to the Acquired
Intellectual Property (collectively referred to hereinafter as "Disputes"), nor,
to Seller's Knowledge, has any such Dispute been threatened, challenging the
legality, validity, enforceability or ownership of or Seller's rights to any
Acquired Intellectual Property.

     (d) To Seller's Knowledge, none of the Acquired Intellectual Property has
been infringed, is being infringed, has been misappropriated, or has been the
subject of any unauthorized use or disclosure. The Seller does not and its
Affiliates do not own or Control any patent or patent application relating to
the Product.

     (e) There is not currently and there has not been previously any pending,
decided or settled or, to Seller's Knowledge, threatened, claim that the use,
development, commercialization or manufacture of the Product, or the use or
exploitation of the Acquired Intellectual Property or Seller, by virtue of its

                                       11

<PAGE>

practice thereof, has infringed, is infringing, or will infringe any
Intellectual Property Rights of any Third Party. Neither Seller nor any of its
Affiliates have granted or created any contractual, legal, or other restriction
on the use of any of the Acquired Intellectual Property other than as set forth
in any document establishing Seller's right to such Acquired Intellectual
Property or in Schedule 4.8 and to Seller's Knowledge, no such restriction
exists. Notwithstanding the foregoing or anything to the contrary herein, Buyer
acknowledges that Seller has not sought or procured a "freedom to operate"
opinion from patent counsel with respect to the development, manufacture,
importation, sale marketing, distribution or other use the Product, and no duty
on the part of Seller to seek or procure such an opinion shall be implied from
this Section 4.8(e) or any other provision hereof.

     (f) All Registered IP included among the Acquired Intellectual Property and
all registered trademarks and service marks, and applications for registration
of trademarks and service marks owned (in whole or in part) by Seller have been
(and all of the foregoing that are licensed to Seller have been, to Seller's
Knowledge) duly registered and/or filed with or issued by each appropriate
Governmental Entity and all necessary maintenance fees have been (or, with
respect to licensed rights have been, to Seller's Knowledge) timely paid to
continue all such rights in effect and such rights have not lapsed or been
cancelled.

     (g) Seller has taken commercially reasonable measures and precautions to
safeguard and maintain the confidentiality of all Acquired Intellectual Property
(except such Acquired Intellectual Property whose value would be unimpaired by
public disclosure). Seller has and enforces a policy requiring each employee and
consultant to execute proprietary information, confidentiality and assignment
agreements substantially in Seller's standard form.

     (h) All fees, annuities, royalties, honoraria and other payments that are
or were due from Seller on or before the Effective Date for any of the Acquired
Intellectual Property or the Assigned Contracts related thereto have been paid.

          4.9 Permits. No violations are or have been recorded in respect of any
     Permit by the entity that issued the Permit, and no proceeding is pending
     or, to Seller's Knowledge, threatened, to suspend, revoke, limit or modify
     either Permit. Exhibit E sets out the status of all outstanding
     Post-Marketing Commitments as of the Effective Date.

          4.10 Regulatory Compliance. Seller has not used in any capacity the
     services of any person debarred under section 306 of the FDCA in connection
     with any work performed on the Product.

          4.11 Stock. All raw materials, finished goods and inventory of Product
     comprising Acquired Assets are saleable and usable for the purpose for
     which it is intended.

          4.12 Product Registration Files. The NDA and IND have been maintained
     in accordance with all Laws and guidance documents in all material
     respects.

          4.13 Information. Seller has made available to Buyer all information
     in its or its Affiliates possession or Control which it reasonably believes
     to be material to the Product, the Acquired Assets and the Assumed
     Liabilities.

                                       12

<PAGE>

          4.14 Affiliates. No Affiliate of Seller owns or controls any assets or
     rights which are material to the Product, and no Affiliate of Seller has
     ever tested, developed, marketed or sold the Product.

          4.15 Ordinary Course. Over the past three (3) months before the
     Effective Date, Seller has not offered any special promotions regarding the
     Product that are substantially different from Seller's past practice
     regarding the Product. Aggregate sales of Product by Seller since October
     1, 2005 have not exceeded US$***.

                                    ARTICLE 5

                     REPRESENTATIONS AND WARRANTIES OF BUYER

          Buyer represents and warrants to Seller as of the Effective Date:

          5.1 Corporate Organization; Authority. Buyer is a corporation, duly
     organized, validly existing and in good standing under the laws of England
     and has all requisite corporate power and authority to conduct its business
     as it is now being conducted and to own, lease and operate its properties
     and assets. Buyer is qualified to do business as a foreign corporation in
     each jurisdiction where the failure to be so qualified would have a
     material and adverse effect on Buyer. Buyer has appointed Dr. Becky
     Prokipcak of CanReg Inc as its agent in the US for regulatory purposes.

          5.2 Authority Relative to this Agreement. Buyer has full corporate
     power and authority to execute and deliver this Agreement and the other
     Transaction Documents to which it is a party and to consummate the
     transactions contemplated hereby and thereby. The execution and delivery by
     Buyer of this Agreement and the other Transaction Documents to which it is
     a party and the consummation of the transactions contemplated hereby and
     thereby have been duly and validly authorized by its Board of Directors,
     and no other corporate proceedings on the part of Buyer are necessary to
     authorize the execution and delivery of this Agreement and the other
     Transaction Documents to which it is a party or to consummate the
     transactions contemplated hereby. This Agreement has been duly and validly
     executed and delivered by Buyer and, assuming this Agreement has been duly
     authorized, executed and delivered by Seller, constitutes the valid and
     binding agreement of Buyer, enforceable against Buyer in accordance with
     its terms, except that such enforcement may be subject to bankruptcy,
     insolvency, reorganization, moratorium (whether general or specific) or
     other similar laws now or hereafter in effect relating to creditors' rights
     generally.

          5.3 No Violations; Consents and Approvals. Neither the execution and
     delivery by Buyer of this Agreement or the other Transaction Documents to
     which it is a party, nor the consummation of the transactions contemplated
     hereby or thereby, will (a) violate any Law, ruling or other restriction of
     any Governmental Entity to which it is subject, (b) breach or violate any
     provision of its constitutional documents, (c) conflict with, result in a
     material breach of, result in the acceleration of, create in any party a
     right to accelerate, terminate or modify or cancel, any Contract to which
     it is a party or by which it is bound, (d) result in the creation of any
     Encumbrance upon any of its assets, or (e) require any material consent,
     waiver, approval, authorization of, permit from, filing with, or
     notification to any Governmental Entity or any other Person in connection
     with its execution delivery and performance of this Agreement and or the
     other Transaction Documents and

                                       13

<PAGE>

     the consummation of the transactions contemplated hereby and thereby,
     except as otherwise expressly contemplated by this Agreement.

          5.4 Litigation. There is not currently and has not previously been any
     action, suit or proceeding pending, decided or settled or, to Buyer's
     Knowledge, action, suit or proceeding threatened, against Buyer before any
     Governmental Entity or arbitral body which will impair or delay Buyer's
     ability to consummate the transactions contemplated by this Agreement, and
     to Buyer's Knowledge, there are no circumstances existing which are likely
     to give rise to any such action, suit or proceeding. Buyer has not received
     notice that it is subject to any outstanding judgment, order, injunction,
     default notice or decree of any Governmental Entity or arbitral body which
     is reasonably likely to materially impair or delay Buyer's ability to
     consummate the transactions contemplated by this Agreement.

          5.5 Brokers and Finders. Neither Buyer nor any of its officers,
     directors or employees has employed any investment banker, broker or finder
     that would impose any liability on Seller for any investment banking fees,
     brokerage fees, commissions or finders' fees in connection with the
     transactions contemplated by this Agreement.

          5.6 Sufficient Funds. Buyer has sufficient financial wherewithal to:
     (a) perform all of its obligations pursuant to this Agreement, including
     payment for the Purchase Price; (b) meet the Post-Marketing Commitments
     outstanding as of the Effective Date as set out in Exhibit E and, to
     Buyer's Knowledge, all other Post-Marketing Commitments; and (c) meet all
     of Buyer's obligations that come due in the ordinary course of business.

          5.7 Post-Marketing Commitments. Buyer acknowledges that from and after
     Closing, Buyer shall be, and hereby is, responsible to the FDA and any or
     all other applicable Governmental Entities for full performance of all the
     Post-Marketing Commitments. Buyer has the necessary expertise to properly
     perform all of the Post-Marketing Commitments. Buyer acknowledges, and the
     Parties agree, that, from and after Closing, Seller will have no further
     obligations whatsoever for, or in connection with, the Post-Marketing
     Commitments.

          5.8 Due Diligence. Buyer has conducted a comprehensive review and
     analysis of all information made available by Seller to Buyer and
     acknowledges that Buyer has been provided adequate access to the personnel,
     properties, premises and records of Seller for such review and analysis.
     EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS AGREEMENT,
     BUYER ACKNOWLEDGES THAT NEITHER SELLER NOR ANY OF ITS AFFILIATES MAKES ANY
     OTHER EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY IN CONNECTION WITH THE
     TRANSACTION CONTEMPLATED BY THIS AGREEMENT.

          5.9 Notice of NDA Updates. Buyer hereby agrees that it will in
     response to written requests received from time to time from Britannia
     Pharmaceuticals, Limited or its nominee inform such Person whether or not
     Buyer has filed an update to the NDA with the FDA since the previous
     request (or in respect of the first such request, since the Closing)
     provided that Buyer's sole liability in respect of a breach of this
     obligation will be to provide the response pursuit to a repeated request.

                                       14

<PAGE>

                                    ARTICLE 6

                               FURTHER ASSURANCES

          6.1 Efforts; Further Assurances. Subject to the terms and conditions
     herein provided, (i) each of Seller and Buyer shall use its respective
     commercially reasonable efforts to obtain all consents, approvals and
     authorizations that are required to be obtained under any Law, and (ii)
     each of Seller and Buyer shall use its respective commercially reasonable
     efforts to effect all necessary registrations and filings and submissions
     of information requested or required by Governmental Entities; in each
     case, as may be required to give full effect to the transactions
     contemplated by this Agreement and the Transaction Documents. Each of
     Seller and Buyer further covenants and agrees, with respect to a threatened
     or pending preliminary or permanent injunction or other order, decree or
     ruling or statute, rule, regulation or executive order that would adversely
     affect the ability of the Parties to consummate the transactions
     contemplated hereby, to use their respective commercially reasonable
     efforts to prevent the entry, enactment or promulgation thereof, as the
     case may be. Each party, shall at the request of the other party, execute
     such documents and do such other acts and things as may be reasonably
     required to vest in Buyer the Acquired Assets and the Assumed Liabilities.

          6.2 Public Announcements. Each Party shall give the other an
     opportunity for prior review and comment on its proposed press release, and
     shall not issue its press release until it has been approved by both Buyer
     and Seller (approval not to be unreasonably withheld or delayed). Neither
     Party shall, and they shall ensure that their respective Affiliates do not,
     otherwise make any public statements with respect to this Agreement and the
     transactions contemplated hereby or issue any press release or make any
     such public statement without the consent of the other Party, except that
     such approval shall not be required for a public statement to the extent
     either Party is advised by its legal counsel that such disclosure is
     required by Law or the rules of a stock exchange to which a Party is
     subject.

          6.3 Fees and Expenses. Except as expressly contemplated hereby, each
     Party agrees to bear its own expenses in connection with the transactions
     contemplated hereby, including fees and expenses of accountants, attorneys,
     investment advisors, and other professionals.

          6.4 Confidentiality. Any confidential information disclosed by one
     Party and/or its Affiliates to the other Party and/or its Affiliates shall
     be subject to the terms of that certain confidentiality agreement by and
     between Mylan Laboratories Inc. and Vernalis (R&D) Ltd dated August 30,
     2005 ("Confidentiality Agreement"), which is incorporated herein by
     reference in its entirety.

          6.5 Transfer Taxes. All sales, use and transfer taxes, including but
     not limited to any value added, stock transfer, stamp duty and real,
     personal, or intangible property transfer taxes, in each case chargeable to
     the Buyer by reason of its acquisition of the Acquired Assets, including
     any interest or penalties in respect thereof (the "Transfer Taxes") shall
     be paid by Buyer. Seller and Buyer shall cooperate with each other and use
     their commercially reasonable efforts to minimize the Transfer Taxes
     attributable to the transfer of the Acquired Assets.

          6.6 Cooperation on Tax Matters.

                                       15

<PAGE>

          (a) Each of Buyer and Seller agree to furnish or cause to be furnished
     to the other, upon request, as promptly as practicable, such information
     (including access to books and records) and assistance relating to the
     Product and any Acquired Assets as is reasonably necessary for the filing
     of any Tax Return, the preparation for, or conduct of, any tax audit, or
     the prosecution or defense of any claim, suit or proceeding relating to any
     proposed tax adjustment relating to the Acquired Assets. Buyer and Seller
     shall keep all such information and documents received by them confidential
     unless otherwise required by Law or the rules of any stock exchange and
     other documents related to taxes as are reasonably necessary to carry out
     the intent of this Agreement.

          (b) Buyer and Seller agree to retain or cause to be retained all books
     and records pertinent to the Acquired Assets until the applicable period
     for assessment of Taxes under Laws applicable to it (giving effect to any
     and all extensions or waivers) has expired, and such additional period as
     necessary for any administrative or judicial proceedings to which it is
     subject to relating to any proposed assessment, and to abide by all record
     retention agreements entered into by it with any taxing authority.

                            ARTICLE 7 INDEMNIFICATION

          7.1 Indemnification Obligation of Seller.

     (a) Seller shall indemnify Buyer, its Affiliates and their respective
stockholders, officers, directors, employees, agents, representatives and
successors and assigns (each a "Buyer Indemnitee" and, collectively the "Buyer
Indemnitees") in respect of, and save and hold each Buyer Indemnitee harmless
against any Losses which such Buyer Indemnitee suffers, sustains or becomes
subject to as a result of or by virtue of, without duplication:

               (i) any facts or circumstances which constitute a
          misrepresentation or breach of any representation or warranty made by
          Seller set forth in this Agreement or any Transaction Document, or in
          any certificate, document or instrument to be delivered by Seller
          pursuant to this Agreement;

               (ii) any non-fulfillment or breach of any covenant of Seller set
          forth in this Agreement;

               (iii) any Excluded Liabilities;

               (iv) any claim by a Third Party for (a) infringement of Third
          Party Intellectual Property Rights; (b) personal injury, death,
          damage to property or other damage, which in each case either (i)
          arises before Closing and relates to activities conducted in relation
          to the Product, the Acquired Assets, or the use, marketing,
          manufacturing or sale of the Product; or (ii) arises on and/or after
          Closing but relates to activities conducted in relation to the
          Product, or the use, marketing, manufacturing or sale of the Product,
          prior to Closing; or

               (v) Seller's negligence or willful misconduct.

                                       16
<PAGE>

          7.2 Indemnification Obligation of Buyer.

     (a) Buyer will indemnify Seller, its Affiliates and their respective
stockholders, officers, directors, employees, agents, representatives and
successors and assigns (each a "Seller Indemnitee" and, collectively the "Seller
Indemnitees") in respect of, and save and hold each Seller Indemnitee harmless
against any Losses which such Seller Indemnitee suffers, sustains or becomes
subject to as a result of or by virtue of, without duplication:

               (i) any facts or circumstances which constitute a
          misrepresentation or breach of any representation or warranty made by
          Buyer set forth in this Agreement or in any Transaction Document, or
          in any certificate, document, or instrument to be delivered by Buyer
          pursuant to this Agreement;

               (ii) any non-fulfillment or breach of any covenant of Buyer set
          forth in this Agreement;

               (iii) any of the Assumed Liabilities;

               (iv) any claim by a Third Party for (a) infringement of Third
          Party Intellectual Property Rights; (b) personal injury, death, damage
          to property or other damage, which in each case arises after Closing
          and relates to activities conducted in relation to the Product, the
          Acquired Assets, or the use, marketing, manufacturing or sale of the
          Product, after Closing; and

               (v) Buyer's negligence or willful misconduct.

          7.3 Indemnification Procedures.

     (a) Any Person making a claim for indemnification pursuant to Section 7.2
or 7.3 above (each, an "Indemnified Party") must give the Party from whom
indemnification is sought (an "Indemnifying Party") written notice of such claim
promptly after the Indemnified Party receives any written notice of any action,
lawsuit, proceeding, investigation or other claim (a "Proceeding") against or
involving the Indemnified Party by any Person or otherwise discovers the
liability, obligation or facts giving rise to such claim for indemnification;
provided, that the failure to notify or delay in notifying an Indemnifying Party
will not relieve the Indemnifying Party of its obligations pursuant to Section
7.2 or 7.3 above, as applicable, except to the extent that such failure or delay
actually harms the Indemnifying Party.

     (b) With respect to the defense of any Proceeding in respect of which an
Indemnified Party would seek indemnification from the Indemnifying Party
pursuant to Section 7.1 or 7.2 above, at its option, an Indemnifying Party may
appoint as lead counsel of such defense any legal counsel approved by the
Indemnified Party, such approval not to be unreasonably withheld or delayed.

     (c) Notwithstanding Section 7.3(b) above: (i) the Indemnified Party will be
entitled to participate in the defense of such claim and to employ counsel of
its choice for such purpose at its own expense, the Indemnifying Party will not
be entitled to assume control of the defense of such claim (and the Indemnified
Party will have the right to control such defense), and the Indemnifying Party
will pay the reasonable fees and expenses of legal counsel retained by the
Indemnified Party, if:

                                       17

<PAGE>

               (i) the Indemnified Party reasonably believes an adverse
          determination of such Proceeding would be reasonably likely to have a
          material and adverse effect upon the Indemnified Party's business;

               (ii) the Indemnified Party reasonably believes that there exists
          a conflict of interest which, under applicable principles of legal
          ethics, could prohibit a single legal counsel from representing both
          the Indemnified Party and the Indemnifying Party in such Proceeding;
          or

               (iii) the Indemnified Party reasonably believes that the
          Indemnifying Party has failed or is failing to prosecute or defend
          vigorously such claim following written notice and a thirty (30) day
          opportunity to cure.

     (d) the Party controlling the claim or proceeding must obtain the prior
written consent of the other Party (which will not be unreasonably withheld,
delayed or conditioned) prior to entering into any settlement of such claim or
Proceeding or ceasing to defend such claim or Proceeding; provided that any such
settlement shall provide for the full release of all claims against the party
whose consent is required.

          7.4 Payment. Upon the determination of the liability under this
     Article 7 or otherwise between the parties or by judicial proceeding, the
     appropriate party shall pay to the other, as the case may be, within twenty
     (20) Business Days after such determination, the amount of any claim for
     indemnification made hereunder. All amounts not paid when due under this
     Article 7 will accrue interest, payable on demand, at a rate equal to the
     lesser of (i) two (2) percent above the prime rate of Citibank per annum
     and (ii) the maximum rate allowable under Law, from the date due until paid
     in full and each paying party will pay the other party's reasonable and
     documented out-of-pocket costs and expenses (including, without limitation,
     reasonable attorneys' fees and expenses) incurred in attempting to collect
     any such amounts.

          7.5 Adjustment for Insurance. The amount of indemnity payable under
     Section 7.2 or Section 7.3 shall be calculated after giving effect to any
     proceeds actually received from insurance policies covering the Loss that
     is the subject of the claim for indemnity, net of any increase in premium
     as a result of such claim.

                                   ARTICLE 8

                               GENERAL PROVISIONS

          8.1 Amendment and Modification. This Agreement may be amended,
     modified or supplemented only by prior written agreement
     signed by the Parties.

          8.2 Waiver of Compliance; Consents. Any failure of any of the Parties
     to comply with any obligation, covenant, agreement or condition contained
     herein may be waived by the Party entitled to the benefits thereof only by
     waiver in writing, but such waiver or failure to insist upon strict
     compliance with such obligation, covenant, agreement or condition shall not
     operate as a waiver of, or estoppel with respect to, any subsequent or
     other failure.

          8.3 Notices. All notices, requests, claims, demands and other
     communications hereunder shall be in writing and shall be deemed to have
     been duly given when delivered in person, by

                                       18

<PAGE>

     confirmed facsimile transmission, confirmed courier service, or by
     registered or certified mail (airmail postage prepaid, return receipt
     requested) to the respective Parties as follows:

          If to Buyer:

          Vernalis (R&D) Limited
          Oakdene Court, Winnersh
          Berkshire, RG41 5UA
          United Kingdom
          Facsimile No.: +44 (0) 118 989 9367
          Attention: Company Secretary

          and

          If to Seller:

          Mylan Pharmaceuticals Inc.
          781 Chestnut Ridge Road
          Morgantown, WV 26505
          Facsimile No.: 304-598-5408
          Attn: Vice President Business Development and Strategic Marketing

          marked to be copied to:

          Chief Legal Officer
          Mylan Pharmaceuticals Inc.
          1500 Corporate Drive, Suite 400
          Cannonsburg, PA 15317
          Facsimile No.: 724-514-1870

or to such other address as the person to whom notice is given may have
previously furnished to the others in writing in the manner set forth above
(provided that notice of any change of address shall be effective only upon
receipt thereof).

          8.4 Assignment. This Agreement and all of the provisions hereof shall
     be binding upon and inure to the benefit of the Parties hereto and their
     respective successors and permitted assigns, but neither this Agreement nor
     any of the rights, interests or obligations hereunder shall be assigned by
     any Party hereto without the prior written consent of the other Party, nor
     is this Agreement intended to confer upon any other person except the
     Parties hereto any rights or remedies hereunder; provided, however, that
     (a) Buyer may assign any or all of its rights, interests and obligations
     hereunder to any Affiliate of Buyer; and provided further, that Buyer may
     assign its rights and delegate its obligations hereunder to (i) any Person
     in connection with a sale of all or substantially all of the Acquired
     Assets, (ii) any Person who acquires all of the capital stock of Buyer, or
     (iii) any Person providing financing to Buyer or its Affiliates; and (b)
     Seller may (i) assign or delegate any or all of its rights interests and
     obligations hereunder to any of its Affiliates or to a successor by way of

                                       19

<PAGE>

     a sale of all or substantially all of the assets of Seller, or a merger or
     similar transaction and (ii) assign any of its rights to payment hereunder
     to any Third Party. This Agreement shall inure to the benefit of, and be
     binding upon, the Parties hereto and their successors and permitted
     assigns.

          8.5 Dispute Resolution. In the event of any claim arising out of or
     relating to any provision of this Agreement, failing resolution of the
     controversy or claim, the matter shall be referred to the Chief Executive
     Officer of Buyer and the President of Mylan Pharms on behalf of Seller who
     shall, as soon as practicable, attempt in good faith to resolve the
     controversy or claim. If such controversy or claim is not resolved within
     fifteen (15) Business Days of the date of initial referral by any Party of
     the matter to the chief executive officers, either Party shall be free to
     initiate legal proceedings in accordance with Section 8.8.

          8.6 Specific Performance. Each of the Parties acknowledge and agree
     that the other Party would be damaged irreparably and could not be made
     whole by monetary damages in the event any of the provisions of this
     Agreement are not performed in accordance with their specific terms or
     otherwise are breached. Therefore, each Party agrees to the granting of
     specific performance of this Agreement and injunctive or other equitable
     relief in favor of the other Party as a remedy for any such breach, in
     addition to any other remedy to which it may be entitled, at law or in
     equity.

          8.7 Disclaimer of Warranties. EXCEPT TO THE EXTENT OTHERWISE EXPRESSLY
     STATED IN THIS AGREEMENT, (a) SELLER HEREBY EXPRESSLY DISCLAIMS ANY
     WARRANTY REGARDING THE VALIDITY OF THE ACQUIRED ASSETS AND MAKES NO
     REPRESENTATION WHATSOEVER WITH REGARD TO THE SCOPE OF THE ACQUIRED ASSETS
     OR THAT THE ACQUIRED ASSETS MAY BE EXPLOITED BY BUYER, ITS AFFILIATES AND
     LICENSEES WITHOUT INFRINGING THE INTELLECTUAL PROPERTY RIGHTS OF OTHERS;
     AND (b) SELLER HEREBY EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED AND EXPRESS
     WARRANTIES INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR
     FITNESS FOR ANY PARTICULAR PURPOSE OF THE ACQUIRED ASSETS OR ANY OTHER
     SUBJECT MATTER OF THIS AGREEMENT.

          8.8 Governing Law and Jurisdiction.

     (a) This Agreement and any claims or disputes arising out of or related to
this Agreement or to the transactions contemplated hereby or to the inducement
of any Party to enter herein (whether for breach of contract, tortious conduct
or otherwise and whether predicated on common law, statute or otherwise) shall
be governed by and construed in accordance with the laws of the State of New
York (regardless of the laws that might otherwise govern under principles of
conflicts of law) as to all matters, including but not limited to matters of
validity, construction, effect, performance and remedies.

     (b) Each Party irrevocably agrees that any legal action, suit or
proceedings against it arising out of or in connection with this Agreement or in
the transactions contemplated hereby or thereby or to the inducement of any
party to enter herein or therein (whether for breach of contract, tortious
conduct or otherwise and whether predicated on common law, statute or otherwise)
shall be brought exclusively in the United States District Court for the
Southern District of New York, or, if such court does not have subject matter
jurisdiction, the state courts of New York located in New York County and hereby

                                       20

<PAGE>

irrevocably accepts and submits to the exclusive jurisdiction and venue of the
aforesaid courts in personam, with respect to any such action or proceeding.

     (c) The New York courts are the most appropriate and convenient courts to
settle any such dispute and each party waives objection to the New York courts
on grounds of inconvenient forum or otherwise as regards proceedings out of or
in connection with this Agreement.

     (d) Each of the Parties agrees that service of any process, summons or
document to such party's respective addresses set forth in Article 8.3 shall be
effective service of process for any action, suit or proceeding in New York with
respect to any matter for which it has submitted to jurisdiction pursuant to
Section 8.8(a). This Section does not affect any other method of service allowed
by law.

     (e) EACH PARTY HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW ANY
RIGHT IT MAY HAVE TO A JURY TRAIL OF ANY LITIGATION, CLAIM OR CAUSE OF ACTION
DIRECTLY OR INDIRECTLY BASED ON OR ARISING OUT OF, UNDER OR IN CONNECTION WITH
THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY IT. EACH PARTY (A) CERTIFIES
THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT
AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY,
AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.8 IN
THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A
TRIAL BY THE COURT.

          8.9 Counterparts. This Agreement may be executed in two (2) or more
     counterparts, each of which shall be deemed an original, but all of which
     together shall constitute one and the same instrument. Facsimile signatures
     will be binding on the Parties and Guarantor.

          8.10 Severability. Any term or provision of this Agreement that is
     invalid or unenforceable in any situation in any jurisdiction shall not
     affect the validity of enforceability of the remaining terms and provisions
     hereof or the validity or enforceability of the offending term or provision
     in any other situation or in any other situation or in any other
     jurisdiction. If the final judgment of a court of competent jurisdiction
     declares that any term or provision hereof is invalid or unenforceable, the
     Parties agree that the court making the determination of invalidity or
     unenforceability shall have the power to reduce the scope, duration, or
     area of the term or provision, to delete specific words or phrases, or to
     replace any invalid or unenforceable term or provision with a term or
     provision that is valid and enforceable and that comes closest to
     expressing the intention of the invalid or unenforceable term or provision,
     and this Agreement shall be enforceable as so modified after the expiration
     of the time within which the judgment may be appealed.

          8.11 Captions. The article and section headings contained in this
     Agreement are solely for the purpose of reference, are not part of the
     agreement of the parties and shall not in any way affect the meaning or
     interpretation of this Agreement.

          8.12 Construction. The language used in this Agreement will be deemed
     to be the language chosen by the Parties to express their mutual intent,
     and no rule of strict construction shall be

                                       21

<PAGE>

     applied against any Party. Any reference to any federal, state, local, or
     foreign statute or law shall be deemed also to refer to all rules and
     regulations promulgated thereunder, unless the context requires otherwise.

          8.13 Entire Agreement. This Agreement, including the documents,
     schedules, certificates and instruments referred to herein, the Transaction
     Documents and the Confidentiality Agreement embody the entire agreement and
     understanding of the Parties hereto in respect of the transactions
     contemplated by this Agreement. There are no restrictions, promises,
     representations, warranties, covenants or undertakings, other than those
     expressly set forth or referred to herein or therein. This Agreement
     supersedes all prior agreements and understandings between the Parties with
     respect to such transactions.

          8.14 Independent Contractors. It is understood and agreed that the
     Parties are independent contractors and nothing contained in this Agreement
     is intended to make either Party a general or special agent, legal
     representative, joint venturer, partner or employee of the other or
     otherwise as participants in a joint or common undertaking for any purpose.
     Personnel supplied by a Party shall work for that Party and shall not, for
     any purpose, be considered as partners, joint venturers, employees or
     agents of the other Party. Each Party assumes full responsibility for the
     acts of its personnel while performing services hereunder and shall be
     responsible solely for their supervision, direction and control,
     compensation, benefits and taxes. Neither party has, expressly or by
     implication, or may represent itself as having, directly or indirectly, any
     authority to act for or on behalf of the other Party or to make contracts
     or enter into any agreements in the name of the other party, or to obligate
     or bind the other party in any manner whatsoever.

          8.15 Interpretation. The parties acknowledge that this Agreement is a
     product of negotiations and that no inference should be drawn regarding the
     drafting or preparation of this Agreement.

          8.16 Guaranty. Subject to (i) the obligation of Seller to provide
     Buyer with any notice required by this Agreement, (ii) the application of
     any applicable cure period set forth in this Agreement; and (iii) the
     non-payment by the Buyer of any amount as and when due under this
     Agreement, Vernalis plc ("Guarantor") hereby guarantees, in favor of
     Seller, (a) the prompt and full performance of the payment obligations of
     Buyer under this Agreement as due on demand of Seller; and (b) the prompt
     and full payment of any amounts owed by Buyer to Seller as due on demand of
     Seller, under this Agreement (the "Guaranty"). Guarantor waives presentment
     notice, dishonor and notice of dishonor and any other defenses (but not
     defenses that Buyer would be entitled to raise against Seller). This
     Guaranty is an absolute, unconditional and irrevocable continuing guaranty
     of the performance of Buyer's obligations and payment under this Agreement.

                                       22

<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed as of the date first written above.

                                        MYLAN PHARMACEUTICALS INC.

                                        By:
                                            ------------------------------------
                                        Print Name:
                                                    ----------------------------
                                        Title:
                                               ---------------------------------

                                        MYLAN BERTEK PHARMACEUTICALS INC.

                                        By:
                                            ------------------------------------
                                        Print Name:
                                                    ----------------------------
                                        Title:
                                               ---------------------------------

                                        VERNALIS (R&D) LIMITED.

                                        By:
                                            ------------------------------------
                                        Print Name:
                                                    ----------------------------
                                        Title:
                                               ---------------------------------

                                        For purposes of Section 8.16:

                                        VERNALIS PLC

                                        By:
                                            ------------------------------------
                                        Print Name:
                                                    ----------------------------
                                        Title:
                                               ---------------------------------

                                       23

<PAGE>

                                    EXHIBIT G
                                Interim Agreement
                                 (see attached)

                                       30

<PAGE>

                                INTERIM AGREEMENT

This Interim Agreement (this "Agreement") is entered into as of November 3,
2005, (the "Effective Date") by and among Mylan Pharmaceuticals Inc., a West
Virginia corporation ("Mylan Pharms"), and Mylan Bertek Pharmaceuticals Inc., a
Texas corporation ("Bertek") (Mylan Pharms and Bertek, individually and
collectively "Seller") and Vernalis (R&D) Limited, an English company ("Buyer").
Buyer and Seller are each sometimes referred to herein as a "Party" and
collectively as the "Parties."

     1. Mylan Pharms is a party to a certain Supply Agreement and associated
Quality Agreement with Vetter Pharma-Fertigung GmbH & Co. KG (the "Vetter
Agreement" and "Vetter") dated as of April 1, 2004, pertaining to the
manufacture of APOKYN(R) (apomorphine hydrocloride for subcutaneous injection)
(the "Product"). The Parties intending to effect an assignment of the Vetter
Agreement from Mylan Pharms to Buyer, have contacted Vetter for the purpose of
facilitating such assignment. Based upon such contact, the Parties believe that
Vetter's consent to such assignment is imminent. The Parties have entered into
this Agreement in order to provide for Buyer the benefits under the Vetter
Agreement.

     2. Mylan Pharms hereby agrees that it will comply with its obligations
under, will not create an encumbrance on, and will not amend or terminate, the
Vetter Agreement until the earliest to occur of (i) Vetter delivers its written
consent to the assignment of the Vetter Agreement to Buyer and assigns the
Vetter Agreement to Buyer in which case Mylan Pharms will not adversely affect
the Vetter Agreement, (ii) Buyer (or an affiliate) and Vetter enter into an
agreement in substitution for the Vetter Agreement and Vetter delivers to Seller
a written release from the Vetter Agreement in form and substance reasonably
acceptable to Seller, and (iii) the second anniversary of the Effective Date. In
no event will this Agreement terminate later than the second anniversary of the
Effective Date. Nevertheless, the Parties recognize that Seller does not
guaranty Vetter will supply Product and that Vetter retains the right to
terminate the Vetter Agreement under circumstances described therein. Seller,
prior to the first to occur of the events described in clauses (i), (ii), or
(iii) above will receive orders for Product from Buyer, place such orders with
Vetter, and otherwise operate to provide to Buyer the benefits of the Vetter
Agreement. Seller shall supply Product to Buyer, such supply to be at the prices
and on exactly the same terms as the Vetter Agreement (with Seller being
substituted for Vetter and Buyer being substituted for Mylan Pharms). Seller
shall also promptly notify Buyer of any notice received under or pursuant to the
Vetter Agreement and consult with Buyer with respect to the response to any such
notice, and if the notice is notice of breach, take all steps required by Buyer
to remedy such breach and avoid termination of the Vetter Agreement

     3. Seller shall promptly notify Buyer of any breach of the Vetter Agreement
by Vetter. To the extent a breach of this Agreement by Seller is caused by a
breach of the Vetter Agreement by Vetter, Seller shall, at Buyer's request and
expense do and take all such actions as Buyer may reasonably request to enforce
the terms of the Vetter Agreement, (including without limitation pursuing any
legal or other action and/or settling any such action, all as directed by
Buyer), and Seller shall not make admissions which might prejudice any such
action. Seller shall also deliver to Buyer all damages and costs recovered
pursuant to, and the benefit of any other remedy and/or

                                       31

<PAGE>

settlement resulting from, any action taken by Seller pursuant to
Buyer's request. The remedy set out in this Section 3 shall be Buyer's sole
remedy for any breach of this Agreement to the extent such breach is caused by a
breach of the Vetter Agreement by Vetter.

     4. Buyer hereby agrees to pay Seller for Product at the time and to the
extent that quantities of Product forecasted by Buyer for purchase for each
month become a firm purchase commitment. Buyer will submit orders to Mylan
Pharms for presentation to Vetter. The price to Buyer for Product shall be that
charged by Vetter to Seller. In the event that Buyer requests Seller to continue
to provide supply chain activity services, analytical testing and quality
services, or other services in connection with making the benefits of the Vetter
Agreement available to Buyer beyond the time required by the Transition Period
Services Agreement due to the continuing existence of this Agreement, Buyer
shall pay thereafter to Seller (i) $*** per month for supply chain activity
services and other services, and (ii) for analytical testing services: $*** per
lot of active pharmaceutical ingredient; $*** per lot of inactive ingredient;
$*** per lot of final product; and $*** per stability test interval. On the
first anniversary of the Effective Date, such charges shall be adjusted to
reflect any increase in the cost of living during the prior 12 months.
Expiration of this Agreement shall be coincidental with the first to occur of
the events set forth in clauses (i), (ii) and (iii) of Section 2 above.

     5. Buyer hereby acknowledges that in order for Mylan Pharms to procure
Product it will be necessary for Buyer to respond promptly to inquiries of Mylan
Pharms from time to time about a variety of matters including, but not limited
to, those having regulatory implications. Buyer agrees to promptly respond as
soon a reasonably practicable to enable Seller to respond to Vetter as required
under the Vetter Agreement to any and all inquiries made by Mylan Pharms for
purposes of acting under the Vetter Agreement. Buyer and Seller hereby agree to
reasonably cooperate to fulfill the intended objectives of this Agreement.
Further, the Parties shall endeavor to establish plans and procedures to
implement operation of this Agreement.

     6. Buyer agrees to indemnify, hold harmless, and defend Seller against any
third party claim made against Seller and all losses, damages, claims, costs,
and expenses, interest, awards, judgments, and penalties awarded against Seller
pursuant to such third party claim, and reasonable attorneys' fees and other
reasonable out-of-pocket costs incurred defending such third party claim
("Damages") to the extent such Damages result from the supply of Product or
performance of services under this Agreement other than those Damages arising
from the default, negligence or willful misconduct of Seller. Seller agrees to
indemnify, hold harmless, and defend Buyer against any and all Losses (as
defined in the Asset Purchase Agreement) arising out of any third party claim
incurred by Buyer or Buyer's Affiliates as a result of the default, negligence
or willful misconduct of Seller under this Agreement other than those Losses (as
defined in the Asset Purchase and Assignment Agreement of even date herewith and
entered into by the Parties) arising from the default, negligence or willful
misconduct of Buyer. The procedures by which a claim for indemnification shall
be brought forward and the payment of any amount due as a result shall be as set
forth in Sections 7.3 and 7.4 of the Asset Purchase and Assignment Agreement of
even date herewith and entered into by the Parties.

     7. Buyer and Seller will use commercially reasonable efforts to obtain from
Vetter consent to an assignment of the Vetter Agreement from Mylan Pharms to
Buyer as soon as possible,

                                       32

<PAGE>

whereupon Mylan Pharms will assign the Vetter Agreement to Buyer. Upon such
assignment, the Vetter Agreement shall become an Assigned Contract for the
purposes of the Asset Purchase and Assignment Agreement made between the Parties
of even date. Buyer will use commercially reasonable efforts to obtain from
Vetter a substitute agreement for the supply of Product as soon as practicable,
if requested by Vetter. Seller will not obstruct Buyer in securing either an
assignment or a separate agreement with Vetter.

     8. . IN NO EVENT SHALL SELLER BE LIABLE TO BUYER FOR INDIRECT, PUNITIVE,
SPECIAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING LOSS OF
PROFITS, AND LOSS OR INTERRUPTION OF BUSINESS. DURING THE FIRST NINETY (90) DAYS
FOLLOWING EFFECTIVE DATE SELLER'S AGGREGATE LIABILITY ARISING FROM OR RELATING
TO ANY BREACH OF THIS AGREEMENT SHALL BE LIMITED TO CORRECTION OR RE-PERFORMANCE
OF THE SERVICES BY SELLER AT SELLER'S EXPENSE. THEREAFTER, THE SELLER'S
AGRREGATE LIABILITY, EXCEPT FOR GROSS NEGLIGENCE OR WILFULL MISCONDUCT, ARISING
FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT SHALL BE LIMITED TO CORRECTION
OR RE-PERFORMANCE OF THE SERVICES BY SELLER AT SELLER'S EXPENSE. This Section 8
shall not be construed to limit a Party's obligations under Section 6.

     9. Seller shall be entitled to terminate this Agreement in the event of a
material breach by Buyer thirty (30) days after receipt by Buyer of written
notice of such breach if such failure is not cured within such thirty (30) day
period. The benefits of this Agreement are personal to Buyer and are not for the
benefit of any successor or assign of Buyer or any other third party. Sections 5
and 7 shall survive the expiration or early termination of this Agreement.

     10. Amendment and Modification. This Agreement may be amended, modified or
supplemented only by prior written agreement signed by the Parties.

     11. Waiver of Compliance; Consents. Any failure of any of the Parties to
comply with any obligation, covenant, agreement or condition contained herein
may be waived by the Party entitled to the benefits thereof only by waiver in
writing, but such waiver or failure to insist upon strict compliance with such
obligation, covenant, agreement or condition shall not operate as a waiver of,
or estoppel with respect to, any subsequent or other failure.

     12. Notices. All notices, requests, claims, demands and other
communications hereunder shall be in writing and shall be deemed to have been
duly given when delivered in person, by confirmed facsimile transmission,
confirmed courier service, or by registered or certified mail (airmail postage
prepaid, return receipt requested) to the respective Parties as follows:

          If to Buyer:

          Vernalis (R&D) Limited
          Oakdene Court, Winnersh
          BERKSHIRE, RG41 5UA
          UNITED KINGDOM
          Facsimile No.: +44 (0) 118 989 9367
          Attention: Company Secretary

                                       33

<PAGE>

          and

          If to Seller:

          Mylan Pharmaceuticals Inc
          781 Chestnut Ridge Road
          Morgantown, WV 26505.
          Facsimile No. 304 598 5408
          Attn: Vice President Business Development and Strategic Marketing

          marked to be copied to:

          Chief Legal Officer
          Mylan Pharmaceuticals Inc.
          1500 Corporate Drive, Suite 400
          Cannonsburg, PA 15317
          Facsimile No.: 724-514-1870

     13. Dispute Resolution. In the event of any claim arising out of or
relating to any provision of this Agreement, failing resolution of the
controversy or claim, the matter shall be referred to the Chief Executive
Officer of Buyer and the President of Mylan Pharms on behalf of Seller who
shall, as soon as practicable, attempt in good faith to resolve the controversy
or claim. If such controversy or claim is not resolved within fifteen (15)
business days of the date of initial referral by any Party of the matter to the
chief executive officers, either Party shall be free to initiate legal
proceedings in accordance with Section 14.

     14. Governing Law and Jurisdiction.

     (a) This Agreement and any claims or disputes arising out of or related to
this Agreement or to the transactions contemplated hereby or to the inducement
of any Party to enter herein (whether for breach of contract, tortious conduct
or otherwise and whether predicated on common law, statute or otherwise) shall
be governed by and construed in accordance with the laws of the State of New
York (regardless of the laws that might otherwise govern under principles of
conflicts of law) as to all matters, including but not limited to matters of
validity, construction, effect, performance and remedies.

     (b) Each Party irrevocably agrees that any legal action, suit or
proceedings against it arising out of or in connection with this Agreement or in
the transactions contemplated hereby or thereby or to the inducement of any
party to enter herein or therein (whether for breach of contract, tortious
conduct or otherwise and whether predicated on common law, statute or otherwise)
shall be brought exclusively in the United States District Court for the
Southern District of New York, or, if such court does not have subject matter
jurisdiction, the state courts of New York located in New York County and hereby
irrevocably accepts and submits to the exclusive jurisdiction and venue of the
aforesaid courts in personam, with respect to any such action or proceeding.

                                       34

<PAGE>

     (c) The New York courts are the most appropriate and convenient courts to
settle any such dispute and each party waives objection to the New York courts
on grounds of inconvenient forum or otherwise as regards proceedings out of or
in connection with this Agreement.

     (d) Each of the Parties agrees that service of any process, summons or
document to such party's respective addresses set forth in Section 12 shall be
effective service of process for any action, suit or proceeding in New York with
respect to any matter for which it has submitted to jurisdiction pursuant to
Section 14(a). This Section does not affect any other method of service allowed
by law.

     (e) EACH PARTY HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW ANY
RIGHT IT MAY HAVE TO A JURY TRAIL OF ANY LITIGATION, CLAIM OR CAUSE OF ACTION
DIRECTLY OR INDIRECTLY BASED ON OR ARISING OUT OF, UNDER OR IN CONNECTION WITH
THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY IT. EACH PARTY (A) CERTIFIES
THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT
AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY,
AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 14 IN
THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A
TRIAL BY THE COURT.

     15. Counterparts. This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Facsimile signatures will
be binding on the Parties and Guarantor.

     16. Severability. Any term or provision of this Agreement that is invalid
or unenforceable in any situation in any jurisdiction shall not affect the
validity of enforceability of the remaining terms and provisions hereof or the
validity or enforceability of the offending term or provision in any other
situation or in any other situation or in any other jurisdiction. If the final
judgment of a court of competent jurisdiction declares that any term or
provision hereof is invalid or unenforceable, the Parties agree that the court
making the determination of invalidity or unenforceability shall have the power
to reduce the scope, duration, or area of the term or provision, to delete
specific words or phrases, or to replace any invalid or unenforceable term or
provision with a term or provision that is valid and enforceable and that comes
closest to expressing the intention of the invalid or unenforceable term or
provision, and this Agreement shall be enforceable as so modified after the
expiration of the time within which the judgment may be appealed.

     17. Interpretation. The parties acknowledge that this Agreement is a
product of negotiations and that no inference should be drawn regarding the
drafting or preparation of this Agreement.

     18. Guaranty. Subject to (i) the obligation of Seller to provide Buyer with
any notice required by this Agreement, (ii) the application of any applicable
cure period set forth in this

                                       35

<PAGE>

Agreement; and (iii) the non-payment by the Buyer of any amount as and when due
under this Agreement, Vernalis plc ("Guarantor") hereby guarantees, in favor of
Seller, (a) the prompt and full performance of the payment obligations of Buyer
under this Agreement as due on demand of Seller; and (b) the prompt and full
payment of any amounts owed by Buyer to Seller as due on demand of Seller, under
this Agreement (the "Guaranty"). Guarantor waives presentment notice, dishonor
and notice of dishonor and any other defenses (but not defenses that Buyer would
be entitled to raise against Seller). This Guaranty is an absolute,
unconditional and irrevocable continuing guaranty of the performance of Buyer's
obligations and payment under this Agreement.

                                       36

<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed as of the date first written above.

MYLAN PHARMACEUTICALS INC.

                                        By:
                                            ------------------------------------
                                        Print Name:
                                                    ----------------------------
                                        Title:
                                               ---------------------------------

                                        MYLAN BERTEK PHARMACEUTICALS INC.

                                        By:
                                            ------------------------------------
                                        Print Name:
                                                    ----------------------------
                                        Title:
                                               ---------------------------------

                                       37

<PAGE>

                                        VERNALIS (R&D) LIMITED

                                        By:
                                            ------------------------------------
                                        Print Name:
                                                    ----------------------------
                                        Title:
                                               ---------------------------------

                                        For purposes of Section 18 only:

                                        VERNALIS PLC

                                        By:
                                            ------------------------------------
                                        Print Name:
                                                    ----------------------------
                                        Title:
                                               ---------------------------------

                                       38<PAGE>

                                                                  Exhibit 4.6(b)

THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST
IN ACCORDANCE WITH RULE 24B-2 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS
AMENDED. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***.

                                LICENSE AGREEMENT

                                 By and between

                       BRITANNIA PHARMACEUTICALS, LIMITED

                                 Redhill, Surrey

                                 United Kingdom

                                       and

                           MYLAN PHARMACEUTICALS, INC.

                        Morgantown, West Virginia, U.S.A.

                                                                  Execution Copy
                                                                        11/24/99

<PAGE>

                                      INDEX

1.   Interpretation and Definitions

2.   Due Diligence Period; Completion of Development; Clinical Trial; Product
     Registration

3.   Grant of License; License Fees

4.   Royalty

5.   Trademarks and Trade Names; Patent Infringement

6.   Representations and Warranties

7.   Confidentiality

8.   Marketing Obligation; Indemnity

9.   Term of License Agreement

10.  Termination

11.  Specific Performance; Force Majeure

12.  Further Assistance

13.  Assignment

14.  Choice of Law

15.  Notices

16.  Miscellaneous

<PAGE>

                                    AGREEMENT

THIS AGREEMENT effective this 29th day of November, 1999, by and between;

BRITANNIA PHARMACEUTICALS, LIMITED, a U.K. limited liability company whose
principle place of business is 41-51 Brighton Road, Redhill, Surrey RH1 6YS,
England (hereinafter referred to as "Britannia"); and

MYLAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws
of the State of West Virginia, United States of America, having its principal
offices at 781 Chestnut Ridge Road, Morgantown, West Virginia, 26505 U.S.A.
(Hereinafter referred to as "Mylan")

                                    RECITALS

A.   Britannia and Dow Hickham Pharmaceuticals Inc., a wholly-owned subsidiary
     of Mylan, previously entered into an agreement dated August 30, 1995 (the
     "1995 Agreement") concerning a product containing apomorphine hydrochloride
     for the treatment of Parkinson's Disease. The 1995 Agreement has been
     terminated.

B.   Britannia's request for Orphan Drug Designation by the United States Food
     and Drug Administration ("FDA") for the Product was granted under the U. S.
     Orphan Drug Act on April 22, 1993 (as hereinafter defined, the "Orphan Drug
     Designation"); and said Orphan Drug Designation (#91-575) subsequently was
     transferred to Mylan on January 14, 1999.

C.   Britannia has developed certain know-how regarding the registration,
     manufacturing and marketing of the Product (as hereafter defined, the
     "Know-How"), and is developing other forms of the Product for intranasal
     and other routes of administration.

D.   Prior to the execution hereof, Mylan has conducted a customary "due
     diligence" review of information within the control of Britannia relating
     to the Product, the Orphan Drug Designation, and the

                                        1

<PAGE>

     Know-How which Mylan deemed necessary and relevant to the transactions
     contemplated by this Agreement.

E.   Mylan filed an Investigative New Drug exemption (the "IND") for the Product
     on March 14, 1997, and is proceeding to conduct the research and testing
     necessary to filing a NDA for the Product.

F.   Britannia, desires to grant Mylan an exclusive license to manufacture,
     promote, use, distribute, sell and otherwise commercially exploit the
     Product under the Know-How in the United States, and under the Know-How in
     Canada and Mexico (as hereafter defined, the United States, Canada and
     Mexico shall constitute the "Territory") and Mylan desires to receive such
     license.

NOW THEREFORE, in consideration of the mutual promises set forth herein, the
parties hereto hereby agree as follows:

1.   INTERPRETATION AND DEFINITIONS

     As used herein, the following terms shall have the respective meanings set
     forth below:

     1.1  "Affiliate" shall mean any person or legal entity controlling,
          controlled by or under common control with the person or legal entity
          with respect to whom such status is at issue.

     1.2  "Best Efforts" shall mean such commercially reasonable efforts,
          resources and expertise as a reasonably prudent business person
          experienced in and knowledgeable of such matters as the kind and
          character contemplated herein would exercise under the circumstances.

     1.3  "Commencement Date" shall mean the date on which this Agreement has
          been signed by both parties.

     1.4  "Contract Year" shall mean the period beginning on the date of
          introduction of the Product by Mylan in the Territory and ending
          December 31 of the following year and, for each

                                        2

<PAGE>

          subsequent Contract Year, the successive calendar year or portion
          thereof during the term of this Agreement.

     1.5  "Field of Use", when used in connection with the Product in the ampule
          dosage form, shall mean the treatment of Parkinson's disease; when
          used in connection with Improvements made by Britannia, shall mean the
          treatment of Parkinson's disease and treatment of any other ailment
          for which Improvements are indicated; and, when used in connection
          with Improvements made by Mylan, shall mean only treatment of
          Parkinson's disease.

     1.6  "Improvements" shall mean new dosage forms or other modifications
          (including new uses outside the Field of Use) to the Product developed
          by either party.

     1.7  "Know-How" shall mean all methods, processes, techniques, products,
          machines, materials, compositions, technology, information, data,
          results of tests, studies, analyses and expertise possessed now and in
          the future by Britannia or any Affiliate of Britannia, or developed
          after the Commencement Date by Mylan or any Affiliate of Mylan, which
          are useful in, and specifically related to, making, marketing or using
          the Product or packaging that is uniquely designed or suited for the
          Product, and shall include, without limitation, pharmacology,
          toxicology, drug stability, manufacturing and formulation
          methodologies and techniques, analytical technologies and clinical or
          non-clinical safety and efficacy studies. It is understood and agreed
          that the "Know-How" does not include any know-how or confidential
          information relating to the Pen as defined in the 1995 Agreement.

     1.8  "NDA" shall mean a New Drug Application filed with the United States
          Food and Drug Administration in respect of the Product for the
          Indication, and all amendments and supplements thereto.

                                        3

<PAGE>

     1.9  "Net Sales" shall mean: The gross amount invoiced for the Product in
          arm's length transactions with bona fide customers who are not
          Affiliates or Sublicensees of Mylan, less

          (a)  quantity and/or normal and customary cash discounts actually
               allowed or taken;

          (b)  freight, postage, insurance, duties and taxes (not including
               sales or income taxes payable by Mylan) invoiced as separate
               items by Mylan;

          (c)  credits, rebates and/or adjustments allowed or given by reason of
               Product expiration dating, rejections or returns, retroactive
               price reductions or programs with wholesalers or other
               distributors or resellers according to which they are entitled to
               chargeback rebates, credits or adjustments upon their sales to
               customers; and

          (d)  rebates, administrative fees, reimbursements or similar payments
               to or for Medicaid or any other government programs (whether
               mandatory or voluntary), hospitals, health maintenance
               organizations, insurance carriers, buying groups or other
               entities in connection with the purchase or utilization of the
               Product.

     1.10 "Net Selling Price" during any period shall mean the amount obtained
          by dividing Net Sales of the Product sold by Mylan during such period
          by the number of units of the Product sold which comprise such Net
          Sales.

     1.11 "Non-Exclusive" shall mean, when used in connection with a specific
          grant of rights to the Product, that the granting party (i) shall
          retain for itself and its Affiliates the ability to use such granted
          rights, and (ii) shall have the ability to authorize its Affiliates or
          third parties (in addition to the grantee of such specific rights) to
          use such granted rights, in the Territory and Field of use covered by,
          and for the time of, the grant.

                                        4

<PAGE>

     1.12 "Orphan Drug Designation" shall mean the FDA's act of granting a
          request by Britannia for designation of the Product as intended for a
          rare disease or condition pursuant to 21 USC 360 bb; which said
          Designation subsequently was transferred to Mylan.

     1.13 "Orphan Drug Rights" shall mean the rights of exclusivity which will
          be granted by the FDA to Mylan upon approval of the Product for
          marketing in the United States pursuant to 21 USC 360 cc.

     1.14 "Product" shall mean a pharmaceutical product containing apomorphine
          hydrochloride in the following dosage forms:

          (a)  2 ml. and 5ml. glass ampules and other containers with the same
               or different volumes for subcutaneous injection; and

          (b)  Improvements developed by Britannia and incorporated under the
               License in accordance with Section 3.3 below.

          It is understood and agreed that "Product" does not include the "Pen"
          as defined in the 1995 Agreement.

     1.15 "Quarter" shall refer to the quarterly periods ending March 31, June
          30, September 30 and December 31.

     1.16 "Specifications" shall mean the specifications for the Product set
          forth in an approved NDA or other regulatory approvals for the Product
          in the Territory, as the same may be amended from time to time in
          writing and agreed between the parties.

     1.17 "Territory" shall mean the United States of America, its territories
          and possessions (including the freely-associated Commonwealth of
          Puerto Rico), Canada and Mexico.

                                        5

<PAGE>

     1.18 "U.K. License" shall mean the license for the Product dated August,
          1993 granted by the Medicines Control Agency in the United Kingdom,
          and all amendments and supplements thereto.

2.   DUE DILIGENCE PERIOD; COMPLETION OF DEVELOPMENT; CLINICAL TRIAL; PRODUCT
     REGISTRATION

     2.1  Mylan shall use its Best Efforts to obtain FDA approval of the NDA for
          the Product and to secure and maintain the registration applications
          for the Product in Canada and Mexico.

     2.2  Britannia agrees to use its Best Efforts to assist Mylan in the
          completion of development work necessary for FDA approval of the NDA
          and in the preparation and filing of the other registrations for the
          Product in the Territory. Out-of-pocket expenses for the NDA and other
          Product registrations, including any additional clinical studies,
          filing fees, and other expenses associated with the completion,
          preparation and filing of the NDA and the other Product registrations,
          shall be borne by Mylan. All product registrations shall be owned by
          Mylan and shall be submitted in Mylan's name.

3.   GRANT OF LICENSE; LICENSE FEES.

     3.1  In consideration for the payment of the license fees provided by
          Section 3.2 hereunder and subject to the terms and conditions hereof,
          Britannia hereby grants Mylan and Mylan hereby accepts an Exclusive
          right under the Know-How and the Orphan Drug Designation, to
          manufacture, market, promote, use, distribute, sell and otherwise
          commercially exploit the Product in the Field of Use in the Territory
          (such rights are hereinafter referred to as the "License"). Mylan
          shall have the right to sublicense the rights granted hereunder,
          provided that the terms and conditions of such sublicense shall not be
          inconsistent with the terms and conditions of this Agreement and each
          such sublicense (except to an Affiliate of Mylan) shall be subject to
          the prior written approval of Britannia, which

                                        6

<PAGE>

          approval shall not be unreasonably withheld. It is understood and
          agreed that any purported sublicense by Mylan in violation of this
          Section 3.1 shall be invalid.

     3.2  In consideration for the rights granted to Mylan pursuant to Section
          3.1 hereof, Mylan hereby agrees to pay the following additional
          license fees to Britannia:

          (a)  U.S. $*** (*** United States Dollars) upon approval by the FDA of
               the NDA with Orphan Drug Rights;

          (b)  U.S. $*** (*** United States Dollars) upon the one year
               anniversary of first commercial sale of the Product in the
               Territory.

     3.3  The License granted hereby shall be deemed to include all Improvements
          to the Product, subject to the following terms and conditions:

          (a)  Improvements developed by Britannia shall become part of the
               License granted to Mylan under Section 3.1 of this Agreement
               without further milestone payments by Mylan provided that Mylan
               shall deliver to Britannia, without charge, a copy of the
               regulatory package for such Improvement in the form in which it
               is filed in the U.S. and other countries in the Territory; Mylan
               shall have the obligation to complete regulatory trials and
               register Improvements developed by Britannia whenever it is
               commercially reasonable to do so;

          (b)  Improvements developed by Mylan within the Field of Use shall be
               offered to Britannia on an exclusive basis for all countries
               outside the Territory;

          (c)  Mylan shall have the right to make, use and sell the Product in
               the Territory under the Improvements developed by Mylan within
               the Field of Use, provided that

                                        7

<PAGE>

               it shall pay to Britannia a royalty of *** percent (***%) on Net
               Sales of such Product;

          (d)  Improvements developed by Mylan outside the Field of Use shall be
               offered to Britannia on an exclusive basis in the U.K. only.
               Mylan shall retain all other rights outside the U.K.; and

          (e)  Mylan shall have the right to make, use and sell Improvements
               without obligations to Britannia other than those established
               under Subsections 3.3(b), (c) or (d) above.

Improvements developed by Mylan shall be offered to Britannia under subsections
(b) and (d) in exchange for a royalty of *** percent of Net Sales of such
Improvement and the parties shall enter into an agreement containing the same
terms and conditions in respect of such Improvement as apply to the Product
under this Agreement. Such Improvements shall be disclosed in writing to
Britannia and Britannia shall have a period not to exceed *** from
date of written disclosure in which to exercise its rights under this Section.
For purposes of this Section 3.3, Improvements developed by Mylan's parent
company, Mylan Laboratories, or its Affiliates shall be deemed to be
Improvements developed by Mylan. The term "developed" as used herein shall mean
reduced to practice such that the party offered the Improvement is able to
determine whether such Improvement would be useful or marketable. The work
required to bring the Improvement to market for regulatory purposes, including
clinical trials necessary for approval, shall remain the responsibility of each
party in its respective territory.

4.   ROYALTY

     In consideration of the grant of license hereinabove set forth, Mylan shall
pay to Britannia a Royalty of ***% of Net Sales for the first *** of the term of
this Agreement and a royalty of ***% of Net Sales thereafter for the remainder
of the term of this Agreement as set forth in Section 9 hereof. Such royalty
shall be paid on a calendar quarterly basis, in arrears, within sixty (60) days
of the end of the quarter in which the royalty is earned.

                                        8

<PAGE>

5.   TRADEMARKS AND TRADE NAMES; PATENT INFRINGEMENT

     5.1  Mylan shall be responsible for the selection, registration and
          maintenance of any trademark or name under which Mylan may choose to
          market the Product and its Improvements. Mylan shall own all
          trademarks and trade names pursuant to which Mylan may determine to
          market the product and its Improvements in the territory.

     5.2  (a)  Britannia and Mylan agree to notify the other in writing of (i)
               any alleged infringement or potential infringement of the Orphan
               Drug Rights, or patents on Improvements; or (ii) any information
               or allegations affecting the validity of the Orphan Drug
               Designation, or patents on Improvements promptly after becoming
               aware of the same.

          (b)  Britannia shall have the option of conducting any litigation with
               respect to alleged infringement of patents on any Improvements
               developed by Britannia. Should Britannia decide to conduct the
               litigation, Britannia shall control the conduct of the litigation
               and Mylan shall reasonably cooperate with Britannia in such
               litigation. Provided, however, should Britannia, for any reason,
               decline to conduct the litigation, Mylan shall have the right to
               conduct such litigation and, in such event, Britannia shall
               reasonably cooperate with Mylan in such litigation.
               Notwithstanding which party conducts the litigation, Mylan and
               Britannia shall equally share the cost of such litigation and any
               proceeds therefrom shall be apportioned, pro rata, between Mylan
               and Britannia based upon the damage sustained by either party,
               respectively, and/or the benefit which inures to each as the
               result of the litigation. The allocation by a court or other
               competent tribunal having jurisdiction shall be binding on the
               parties. If the matter is not determined by a court or other
               tribunal or, if the court or tribunal

                                        9

<PAGE>

               does not make such an allocation, or if the matter is resolved by
               settlement or other mechanism, the parties shall negotiate in
               good faith to agree on an appropriate allocation.

          (c)  Britannia and Mylan, each at the request of the other and at
               their own expense, shall assist each other and cooperate in any
               action taken, other than direct financial assistance, against an
               alleged infringer or potential infringer.

     5.3  Britannia agrees to defend (or settle) at its own expense, any action
          in the nature of patent infringement asserted against Mylan by reason
          of the marketing and sale of the Product pursuant to the Orphan Drug
          Rights, patents on Britannia's Improvements and/or the Know-How and to
          indemnify Mylan against any cost, loss or expense (including
          reasonable attorneys fees and disbursements) incurred in connection
          therewith. Any such indemnification shall be provided in the manner
          and subject to the terms of Sections 8.3 and 8.4 hereof, provided that
          Britannia shall only be responsible for direct costs, damages and
          expenses arising from a matter as to which indemnification is required
          by this Section (including, without limitation, license fees paid
          hereunder and other costs and expenses directly attributable to such
          matter) and shall not be responsible for lost profits or consequential
          damages (such as loss of corporate good will generally) arising with
          respect thereto. Notwithstanding the preceding provisions of this
          Section 5.3, Mylan shall be responsible for the first $*** in costs
          and expenses attributable to any matter as to which indemnity is to be
          provided under this Section 5.3.

6.   REPRESENTATIONS AND WARRANTIES

     6.1  Britannia hereby represents and warrants to Mylan as follows:

                                       10

<PAGE>

          (a)  The execution and delivery by Britannia of this Agreement and the
               performance by Britannia of its obligations hereunder have been
               duly authorized by all necessary corporate action on the part of
               Britannia, and do not conflict with the terms of any other
               contract, agreement, arrangement or understanding to which
               Britannia is a party.

          (b)  Britannia has not received notice nor is it aware of any claim of
               ownership invalidity or patent infringement asserted by any third
               party (including, without limitation, by employees, consultants
               or other personnel) against Britannia in respect of the Know-How.

          (c)  Britannia has the right to grant an exclusive license under the
               Know-How in accordance with the terms and conditions hereof.

          (d)  Britannia has provided, or otherwise made available, to Mylan,
               whether requested or not, all relevant or material information
               and data concerning the Product, Orphan Drug Designation, the
               Know-How and the ability of Britannia to perform hereunder.

          (e)  To Britannia's knowledge and belief, all information provided or
               to be provided by Britannia hereunder, as far as it is or shall
               be known by Britannia, is true, complete and accurate.

          (f)  To Britannia's knowledge and belief, there are no pending or
               threatened actions, suits, proceedings, investigations, inquiries
               or judgements, decrees, injunctions, awards, or orders involving,
               or related to, any matters set forth herein or rights granted
               hereunder.

     6.2  Mylan hereby represents and warrants to Britannia as follows:

                                       11

<PAGE>

          (a)  The execution and delivery by Mylan of this Agreement and the
               performance by Mylan of its obligations hereunder have been duly
               authorized by all necessary corporate action on the part of Mylan
               and do not conflict with the terms of any other contract,
               agreement, arrangement or understanding to which Mylan is a
               party.

          (b)  Mylan has received from Britannia such information with respect
               to the Product, Orphan Drug Designation and the Know-How as Mylan
               has deemed necessary and relevant in connection with the
               transactions contemplated by this Agreement, and Mylan has had
               the opportunity to ask questions of and receive answers from
               persons acting on behalf of Britannia as Mylan has deemed
               necessary to verify the information so obtained. The foregoing
               shall not be deemed a limitation upon any representation or
               warranty of Britannia set forth herein. This representation shall
               come into effect upon expiration of the Due Diligence Period
               referred to in Section 2.1 provided Mylan has not terminated this
               Agreement in accordance with that Section.

     6.3  Each of Mylan and Britannia hereby covenant with each other as
          follows:

          (a)  Mylan shall disclose to Britannia and Britannia shall disclose to
               Mylan, in each case within five (5) business days, all reports or
               other knowledge ("Safety Data") they may from time to time
               possess with respect to "adverse drug experiences" (as defined in
               regulations promulgated by applicable regulatory authorities),
               mislabeling, stability failures or microbiological contamination
               with respect to the product (whether occurring inside or outside
               the Territory). With respect to "serious adverse drug
               experiences" as defined in the U.S. legislation in 21 CFR Section
               312.32 and Section 314.80 and in applicable sections of the laws
               of the countries comprising the Territory, each party shall
               disclose to the other such Safety Data within

                                       12

<PAGE>

               two (2) business days of receipt of notification of such event.
               The content of such disclosure shall comply with applicable
               regulations. Each party shall promptly deliver to the other all
               correspondence which such party may receive from regulatory
               authorities in jurisdictions where such party has rights to
               market the product, except for procedural, non-substantive
               communications which do not relate to the safety or efficacy of
               the Product.

7.   CONFIDENTIALITY

     7.1  For purposes of this Agreement, the term "Confidential Information"
          shall mean any information (whether or not reduced to writing) which
          either party shall possess in relation to the development,
          formulation, manufacture, testing, marketing or distribution of any
          Product (including Improvements developed by Mylan) except for any
          information which:

          (a)  is available to the public generally other than as a result of
               disclosure by either party;

          (b)  is known to a party prior to disclosure by the other party and
               such other party can prove it by written evidence or other
               competent proof; or

          (c)  becomes known to a party by a source other than the other party,
               which source is legally entitled to make such disclosure.

     7.2  Britannia and Mylan shall keep in strictest confidence all
          Confidential Information and shall not disclose such Confidential
          Information to any third person except employees, consultants or other
          agents who need to receive such Confidential Information for the
          purpose of achieving an objective of this Agreement and who are bound
          by obligations

                                       13

<PAGE>

          of confidentiality with respect thereto, as necessary in connection
          with the transactions provided for or contemplated hereby, or as may
          otherwise be required by law. Each such party shall exercise all
          necessary precautions to safeguard the secrecy of Confidential
          Information and to prevent the unauthorized disclosure thereof.

     7.3  Subject to Sections 7.1 and 7.2, Mylan (and Mylan's permitted
          sublicensees) shall have the right to use all Confidential Information
          hereafter developed by Britannia for use in marketing the product in
          the Territory and for developing Improvements but for no other
          purpose.

     7.4  The provisions of this Article 7 shall survive expiration or
          termination of this Agreement for any reason and shall remain in
          effect for a period of seven (7) years following the date of the last
          sale of Product or any Improvement by Mylan hereunder.

8.   MARKETING OBLIGATION; INDEMNITY

     8.1  At all times during the term hereof following the Commencement Date,
          Mylan will use its Best Efforts, subject to compliance with all
          applicable laws and regulations, to register, promote and market the
          Product in the Territory. Mylan agrees to market the Product in a
          commercially reasonable manner.

     8.2  Britannia shall indemnify and hold Mylan harmless from and against any
          direct costs, expenses (including, without limitation, reasonable
          attorneys fees) or damages (hereinafter referred to as "Claims") which
          arise from breach by Britannia of any of its representations,
          covenants, warranties or obligations set forth herein, except to the
          extent such Claims are caused by the negligence or willful misconduct
          of Mylan. Mylan shall indemnify and hold Britannia harmless from and
          against any Claims which arise from the breach by Mylan of any of its
          representations, covenants, warranties or

                                       14

<PAGE>

          obligations set forth herein or from the marketing, sale or
          distribution of the Product by Mylan and its Affiliates, except to the
          extent such Claim was caused by or arises from: (i) the negligence or
          willful misconduct of Britannia; or (ii) any matter as to which
          Britannia has agreed to indemnify Mylan hereunder. The person
          obligated to provide indemnity pursuant to this Section 8.2 is
          hereinafter referred to as the "Indemnifying Party".

     8.3  Promptly after the receipt by any party hereto of notice of (a) any
          claim or (b) the commencement of any action or proceeding, such party
          will, if a claim with respect thereto is to be made against any party
          obligated to provide indemnification pursuant to Section 8.2 hereof,
          give such Indemnifying Party written notice of such claim or the
          commencement of such action or proceeding. Such Indemnifying Party
          shall have the right, at its option, to compromise or defend, at its
          own expense and by its counsel, any such matter involving the asserted
          liability of the party seeking such indemnification. Such notice, and
          the opportunity to compromise or defend, shall be a condition
          precedent to any liability of the Indemnifying Party under the
          indemnification provisions of Section 8.2. In the event that any
          Indemnifying Party shall undertake to compromise or defend any such
          asserted liability, it shall promptly notify the party seeking
          indemnification of its intention to do so, and the party seeking
          indemnification agrees to cooperate fully with the Indemnifying party
          and its counsel in the compromise of, or defense against, any such
          asserted liability. In any event, the indemnified party shall have the
          right, at its own expense, to participate in the defense of such
          asserted liability, provided that the Indemnifying Party's counsel
          shall make all final decisions concerning the defense or compromise or
          settlement of such litigation.

     8.4  Each of the parties hereto shall be entitled to be represented at any
          proceedings brought by the other party under this Article 8 by its own
          counsel, at its own expense, and shall

                                       15

<PAGE>

          cooperate fully with the other party in any such proceeding, provided
          it is adequately reimbursed for its out-of-pocket costs and expenses,
          excluding attorneys' fees.

     8.5  Mylan at all times under this Agreement shall maintain product
          liability insurance protecting itself and Britannia (naming Britannia
          as an additional insured) against any Claims for which Mylan is
          required to indemnify Britannia hereunder. The insurance coverage
          shall be in such amounts, covering such risks as are appropriate, in
          accordance with sound business practice and Mylan's obligations under
          this Agreement, but, in any event in amounts ***.
          In connection with its obligations hereunder, Mylan, upon request,
          shall furnish proof of such insurance to Britannia.

9.   TERM OF LICENSE AGREEMENT

     9.1  Subject to the provisions of Section 11, this Agreement shall remain
          in effect until the last to expire of the following terms:

          (a)  Expiration of the Orphan Drug Rights;

          (b)  The last to expire of any patents issued or licensed to Britannia
               for an Improvement or, if there are no such patents, for a period
               of *** from the date of first commercial sale of the
               Product in the Territory subject to a right by Mylan to renew for
               additional consecutive terms of *** each by giving
               notice in writing to Britannia of its intent to renew not less
               than six (6) months prior to the end of the initial or any
               renewal term.

     9.2  Upon the expiration of the term of this Agreement, Mylan shall have a
          royalty-free, Non-Exclusive, paid-up license to market, promote, use,
          sell and distribute the Product under the Trademarks in the Territory.

                                       16

<PAGE>

     9.3  No expiration of the term of this Agreement shall relieve either party
          of obligations accrued to such date of expiration or of obligations
          which continue by the terms hereof beyond such expiration.

10.  TERMINATION

     10.1 In the event of any default by either party in the performance of any
          of the terms and conditions of this Agreement, the other party may
          terminate this agreement upon ninety (90) days written notice;
          provided, however, that (i) if during such ninety (90) day period the
          party against whom the default is claimed cures default, (ii) if such
          breach cannot be cured within such ninety (90) day period, such person
          takes reasonable steps to commence and proceeds diligently thereafter
          to cure such default and, in fact, cures such default within a
          reasonable period of time, or (iii) if such default is cured in any
          other manner satisfactory to the other party as a substitute for full
          performance, then this Agreement will continue in full force and
          effect until it expires as provided in Section 9.

     10.2 In the event that this Agreement is terminated by either party as a
          result of the default of the other party, the obligations of
          confidentiality set forth in Section 7 shall survive and continue to
          bind the defaulting party, and in all other respects the rights and
          obligations of the non-defaulting party shall be determined in
          accordance with the provisions of this Agreement.

11.  SPECIFIC PERFORMANCE; FORCE MAJEURE

     11.1 Each party agrees that a violation by it of any of its covenants and
          undertakings contained in this Agreement will cause irreparable injury
          to the other, and that such other party shall be entitled, in addition
          to any other rights and remedies it may have hereunder at law or at
          equity, to an injunction or similar

                                       17

<PAGE>

          equitable remedy enjoining and restraining any such violation or
          threatened violation thereof.

     11.2 Neither Britannia nor Mylan shall be held liable or in default for
          failure of performance for any cause beyond its reasonable control
          including, for example, Acts of God, declared or undeclared war, fire,
          flood, interruption of transportation, embargo, insurrections,
          accident, explosion, governmental laws, orders, regulations, or
          restrictions, any strike, lockout or other labor troubles interfering
          with the production or transportation of the Product.

12.  FURTHER ASSURANCES

     Each of the parties shall, from time to time during the term of this
Agreement, upon request by the other, execute and deliver all such further
documents or instruments as may be required in order to give effect to the
purpose and intent of this Agreement. Without limiting the generality of the
foregoing, the obligations of the parties hereunder are undertaken with a
principal objective of complying with all pertinent provisions of applicable
laws, orders and regulations relating to the manufacture, use or sale of
pharmaceutical products, and the parties shall take all necessary action as may
be required to comply with such provisions.

13.  ASSIGNMENT

     This Agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective assignees and successors in interest. In
addition, except to the extent of the sublicensing permitted by Section 3.1,
neither party shall assign its rights or obligations hereunder, except with the
consent of the other party, which consent shall not be unreasonably withheld.

14.  CHOICE OF LAW

     This Agreement shall be governed by, and construed in accordance with, the
internal laws of the State of Delaware, without giving effect to its principles
of conflicts of laws.

                                       18

<PAGE>

15.  NOTICES

     Any such notice, request or other communication required or permitted by
this Agreement to be given by either party to the other shall be in writing and
either mailed by registered or certified mail, return receipt requested, by
express delivery service or by facsimile transmission, addressed to such party,
Attention: The Chief Executive Officer, at its address indicated above or to
such party previously may have designated by like written notice. Notice shall
be deemed to have been given upon receipt. Facsimile transmission numbers for
the parties are as follows:

          If to Mylan: (304) 599-7284

          If to Britannia: (44) (1) 737 762 672

16.  MISCELLANEOUS

     16.1 This agreement constitutes the entire agreement between the parties
          with respect to the subject matter hereof and supersedes all prior
          written or oral agreements or understandings regarding the subject
          matter hereof or in conflict with its terms.

     16.2 Except as otherwise provided in Section 11.1, any disputes arising
          with respect to the interpretation or enforcement of, or claims with
          respect to, any provision hereof shall be submitted in the first
          instance to the parties' respective Chief Executive Officers.

     16.3 No modification or waiver of any of the terms of this Agreement shall
          be deemed valid unless it is in writing and signed by the party
          against whom such modification is sought to be enforced. The failure
          of either party to insist upon the strict performance of any term of
          this Agreement or the waiver by either party of any breach under this
          Agreement shall not prevent the subsequent strict enforcement of such
          term nor be deemed a waiver of any subsequent breach.

                                       19

<PAGE>

     16.4 In the event any court declares illegal or unenforceable, as written
          or applied, any provision of this Agreement, the balance of such
          provision and this Agreement shall continue in full force and effect
          as if such provision had been deleted or made inapplicable to the
          situations to which such provision cannot be legally applied.

     16.5 Neither party shall publicly disclose the subject matter or terms and
          conditions hereof without the prior consent of the other, except to
          the extent of disclosure which either party may be required to make by
          law or regulation.

     IN WITNESS WHEREOF, the parties hereto have executed this agreement as of
the day and year first written above.

                                        BRITANNIA PHARMACEUTICALS, LIMITED

                                        By:
                                            ------------------------------------

                                        MYLAN PHARMACEUTICALS INC.

                                        By:
                                            ------------------------------------

                                       20

<PAGE>

                     AMENDMENT TO LICENSE AGREEMENT BETWEEN

                       BRITANNIA PHARMACEUTICALS, LIMITED

                                       AND

                           MYLAN PHARMACEUTICALS INC.

                             DATED NOVEMBER 24, 1999

The Parties agree to amend the above referenced agreement as follows:

1.   Section 3.3(a) shall be deleted and replaced with the following:

     3.3(a) Improvements developed by Britannia shall become part of the License
            granted to Mylan under Section 3.1 of this Agreement without further
            milestone payments by Mylan provided that Mylan shall by written
            notice elect to accept rights to the relevant Improvement *** the
            date of written disclosure of such Improvement by Britannia and
            provided that Mylan shall deliver to Britannia, without charge, a
            copy of the regulatory package for such Improvement in the form in
            which it is filed in the U.S. and other countries in the Territory;
            Mylan shall have the obligation to complete regulatory trials and
            register Improvements developed by Britannia and accepted by Mylan
            as aforesaid whenever it is commercially reasonable to do so;

2.   Revise Page 8 Line 14 as follows:

     By inserting the sentence:

     "All Improvements shall be disclosed in writing and each party shall have a
     period *** the date of written disclosure to exercise
     its rights under this Section 3.3"

     In place of the sentence:

     "Such improvements shall be disclosed in writing to Britannia and Britannia
     shall have a period *** the date of written disclosure in which to exercise
     its rights under this Section"

Signed and Accepted:-

MYLAN PHARMACEUTICALS INC.              BRITANNIA PHARMACEUTICALS LTD.

BY:                                     BY:
    ---------------------------------       ------------------------------------
TITLE:                                  TITLE:
DATE:                                   DATE:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}]]